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ABSTRACT 
 
 
The adaptor protein CT10-Regulator of Kinase (CRK) and the closely related 
CRK-Like (CRKL) are adaptor proteins that play important roles in many signaling 
pathways regulating cell proliferation and cell motility. A notable example is their 
required role in Reelin signaling during development of the laminated structures of the 
vertebrate central nervous system, including the cerebral cortex, cerebellum, 
hippocampus, and retina. As adaptors, CRK/CRKL are important in coupling 
phosphotyrosine signaling to G protein activity to regulate both cell proliferation and 
changes in the actin cytoskeleton, thereby exerting control over cell motility, and 
migration. While many proteins that interact with CRK/CRKL have been identified, the 
diverse roles of these molecules suggest that more remain to be found. 
 
Herein is described a novel CRK/CRKL interacting protein, Src Homology 2 
domain-containing protein D (SHD), which demonstrates a phosphorylation-dependent 
interaction with the CRK/CRKL SH2 domain in HEK 293 cells stimulated with 
hydrogen peroxide, which globally boosts tyrosine phosphorylation by inhibiting 
tyrosine phosphatases. Treatment with an inhibitor for Src family kinases (SFKs), Src-
1, or an inhibitor of Abl/Arg kinases, STI571, reduces peroxide-induced binding of the 
CRKL-SH2 domain to SHD. We show that overexpression of Abl kinase, but not the 
SFK Fyn is sufficient to induce binding of the CRKL-SH2 to SHD and that this 
interaction requires at least one of the five tyrosines in YxxP motifs found in SHD. 
Using mass spectrometry, we found that Abl phosphorylates SHD on Y144, which is 
located in a YxxP motif. Mutation of this site to phenylalanine reduces, but does not 
prevent, Abl-induced binding of SHD to the CRKL-SH2 domain, suggesting that other 
YxxP sites also facilitate the interaction. A discussion of the cellular consequences of 
the interaction between SHD and CRK/CRKL is presented. 
 
To explore the biological role of SHD, we used the zebrafish to study shdb, a 
putative ortholog of human SHD. The expression of shdb was unknown and so we 
performed in situ hybridization and determined that shdb was expressed in the 
developing nervous system. To study the function of this gene, we used a morpholino 
to knock down expression of shdb which resulted in significantly reduced eye size. 
Possible roles of Shdb in eye development are discussed as is future research aimed to 
elucidate the cellular and developmental mechanisms by which Shdb functions in the 
developing eye. 
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CHAPTER 1: REVIEW OF THE ROLES OF CRK/CKRL IN SIGNALING 
 
1.1. Introduction 
Protein phosphorylation constitutes a major mechanism of signaling and 
regulation in eukaryotes which is required for many cellular processes.  Enzymes known 
as kinases catalyze the transfer of δ-phosphate from ATP to the free hydroxyl group onto 
tyrosine, threonine, or serine residues of target proteins.  The additions of the negatively-
charged phosphate group to a protein can have two major consequences.  
Phosphorylation can alter the activity of proteins with enzymatic activity or create 
docking sites for other proteins.  Actions mediated by phosphorylation are readily 
reversible by phosphatases, enzymes which remove phosphate groups from proteins.  In 
addition to regulating other enzymes, phosphorylation regulates kinases and phosphatases 
themselves.  By regulating the activity level and localization of kinases and phosphatases, 
the cell tightly controls protein phosphorylation both spatially and temporally to produce 
an appropriate response to external signals.  This is an important balance for cells to 
maintain and many disease states result from misregulation of phosphorylation including 
cancers and developmental disorders [51, 107]. 
Protein phosphorylation was first discovered by Phoebus Levene in the early 
1900s [72].   Phosphoserine was specifically discovered in the 1930s by Fritz Lipmann 
[76].  However, phosphorylation on tyrosine was not identified until the 1970s [52].  This 
is in part due to the relative abundance of phosphoamino acids in the cell.  Phosphoserine 
accounts for as much as 90% of the phosphorylated amino acid content in the cell, with 
phosphothreonine accounting for another ~9%, and phosphotyrosine typically making up 
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~1% [51].  Despite this,  17% (90 of 540 kinases encoded in the human genome) are 
tyrosine kinases [82, 102].  In addition, humans have 108 tyrosine phosphatases [52], and 
the half-life of phosphotyrosine is brief compared to phosphoserine and 
phosphothreonine, sometimes lasting only a few seconds [66].  These observations 
highlight the importance of tyrosine phosphorylation as a particularly tightly regulated 
mechanism for cell signaling. 
The best characterized tyrosine phosphorylation events are the actions of 
Receptor Tyrosine Kinases (RTKs), a group of transmembrane protein kinases that 
transduce many external signals influencing cell growth, migration, differentiation, 
division, and death [51, 107].  RTKs bind ligands such as EGF, VEGF, PDGF, and NGF, 
leading to dimerization of the receptor and trans-autophosphorylation of their 
intracellular domains [52].  The phosphorylated tyrosine residues on the intracellular 
domain then act as docking sites, recruiting relevant downstream proteins to the cell 
membrane and bringing them into proximity with other proteins necessary to propagate 
the signal.  Non-receptor Tyrosine Kinases (TKs) have also been characterized and 
function in the cytoplasm to phosphorylate proteins not only at the membrane but also in 
the cytoplasm or nucleus [52].  Perhaps the most well studied non-receptor tyrosine 
kinase is Src.  The Src kinase is a ubiquitously expressed protein integral to many cell 
functions.  It was originally characterized in its viral form, v-Src from a chicken virus, 
where it was found to be the gene product sufficient for tumor formation by its intrinsic 
kinase activity [17, 73, 104].  A cellular homolog, c-Src was soon discovered and 
identified specifically as a tyrosine kinase [8, 18, 53].  The many functions and 
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interactions of Src kinase could fill several books, but some notable roles include cell 
growth, differentiation, adhesion, and motility [8].  Indeed, an entire group of related 
tyrosine kinases are known collectively as Src Family Kinases (SFKs), of which Src, Fyn, 
and Yes are the most widely expressed and ubiquitous [120]. 
Once a tyrosine residue has been phosphorylated by a kinase, it can serve as a 
binding site for proteins which contain either a Src Homology 2 (SH2) or 
Phosphotyrosine Binding (PTB) domains.  These interactions are not only dependent on 
the phosphorylated tyrosine.  PTB and SH2 domains all display preferences for specific 
amino acid motifs near the phosphorylated tyrosine, allowing for high precision in the 
protein-protein interactions mediated by phosphotyrosine [34, 131]. 
The discovery of modular protein domains such as the SH2 domain led to a new 
understanding in cell biology where protein-protein binding through scaffold and adaptor 
proteins often results in the formation of large signaling complexes.  Scaffolds and 
adaptors are proteins which typically lack enzymatic activity and function by acting as 
intermediaries, binding proteins via modular protein domains.  Both scaffolds and 
adaptors function by controlling the localization of proteins to initiate, propagate, and 
amplify signals within the cell.  Although the difference between scaffold and adaptor 
proteins is not well defined in the literature, and they are sometimes used 
interchangeably, it has become colloquially accepted that the terms refer to distinct types 
of molecules.  Scaffold proteins are typically larger, associate with specific structures 
within the cell, and often have multiple sites that facilitate the same interaction.  The 
scaffold protein CRK (chicken tumor virus CT10-Regulator of Kinase) Associated 
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Substrate (CAS) is an excellent example of a stereotypical scaffold protein.  CAS is a 
relatively large (130kDa) protein which localizes to focal adhesions, becomes 
phosphorylated after integrin activation, and contains up 16 sites that when 
phosphorylated mediate the binding of CRK-SH2 [45, 67].  Adaptor proteins are 
generally smaller, mobile in the cell, and contain two or more modular protein domains 
or protein-protein binding regions.  The above-mentioned protein CRK and its close 
relative CRKL (CRK-like) contain an SH2 domain, one or two SH3 domains, and are 
classic examples of adaptor proteins.  They function by localizing proteins bound to their 
SH3 domain to substrates of their SH2 domain upon phosphorylation of the appropriate 
site on targets such as CAS [45, 67].  The actions of scaffolds and adaptors can be 
roughly described with an analogy where scaffold proteins act as the baseball stadium 
where the game will be played, and the adaptor acts as the bus that brings all the players 
to the game. 
 
1.2 . The CRK/CrkL Adaptor Proteins: 
CRK and CRKL are ubiquitously expressed adaptor proteins with numerous 
functions and a rich history [32, 96].  CRK was first identified by Bruce Mayer as a viral 
oncogene in an avain sarcoma virus which shared some sequence homology with the 
mammalian SH2 domains of tyrosine kinases and the enzyme phospholipase C [83].  It 
had previously been demonstrated that this avian virus caused tumors to form when 
injected into chickens [56].  The transforming factor was identified and termed p47
gag-crk
, 
later renamed v-Crk after discovery of its cellular homolog [83, 84].  v-Crk alone was 
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sufficient to cause transformation, and it was observed that v-Crk selectively increased 
phosphorylation on some proteins including endogenous kinases, despite lacking any 
tyrosine kinase activity itself [7, 83, 84].  This was intriguing and puzzling at the time, 
but we now know that fusion of CRK to the viral gag protein results in translocation of v-
CRK to the cell membrane, an event that facilitates the cellular actions of CRK through 
activators bound to its SH3 domain [7, 84].  In normal cells, localization of c-CRK to the 
membrane is tightly controlled by phosphorylation events. 
Our understanding of these adaptor proteins has grown a great deal since these 
first discoveries.  In humans, CRK occurs in three isoforms: CRK-I, CRK-II, and CRK-
III, while CRKL occurs as only a single splice product [7].  CRK-II is the predominant 
isoform in most cells and is similar in structure to CRKL.  Both CRK-II and CRKL 
contain an SH2 domain near the N-terminus, a flexible linker region, followed by two 
SH3 domains [68].  The isoform CRK-I lacks the C-terminal SH3 domain, but still 
contains one SH2 and one SH3 domain [7].  CRK-III contains an SH2 domain, an SH3 
domain, and a partial second SH3 domain [16].  The SH2 domains of CRK and CRKL 
have been found to bind to target proteins with phosphorylated tyrosine in a YxxP motif 
[131].  The SH3 domain binds to proline rich regions on proteins with the preferred 
consensus motif PxxPxK [4, 16].  This structure allows CRK and CRKL to act at the 
heart of many signaling events, where it facilitates the formation of large signaling 
networks that can incorporate many, often opposing signals to produce a unified output 
signal and direct an appropriate cellular response. 
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1.3 . CRK and CRKL in Cell Signaling: 
The actions of CRK and CRKL seem relatively simple, and yet achieve a wide 
array of functions in the cell which can cause disease when aberrant.  Both these 
molecules function by binding two other proteins.  The SH3 domain binds to proline rich 
regions (PXXPXK) on target proteins including the guanine nucleotide exchange factors 
(GEFs) C3G, Dock180, and SOS, and kinases such as c-Abl and JNK.  The CRK/CRKL 
SH2 domain targets a large and growing list of proteins including Paxcillin, Signal 
Transducer and Activator of Transcription 5 (STAT5), Endothelial and smooth muscle 
cell-derived neuropilin-like protein (ESDN), also known as Discoidin, CUB and LCCL 
domain containing 2 (DCBLD2), Crk Associated substrate of Src (CAS), and Disabled-1 
(Dab-1) [4, 68]. 
CRK and CRKL were initially of interest because of the oncogenic properties of 
v-CRK, which in cells increases phosphorylation despite lacking any kinase activity.  The 
role of these proteins in cancer became apparent when it was shown that CRKL is 
responsible for transmitting the effect of the BCR-Abl fusion protein which causes 
Chronic Myelogenous Leukemia (CML) [91, 92].  CML accounts for approximately 15% 
of Leukemia cases in adults [30].  Fortunately, it is now amongst the most treatable forms 
of cancer thanks to intensive research and rational drug design resulting in the production 
of Imatinib, an inhibitor of the Abl tyrosine kinase [59, 90].  The BCR/ABL fusion 
protein is the product of the Philadelphia chromosome (Ph), named for the city where it 
was discovered by David Hungerford and Peter Nowell in 1959 [127].  Caused by a 
reciprocal translocation between chromosome 9 and 22, BCR-Abl acts as a constitutively 
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active Abl kinase.  This is caused by the BCR fusion which results in loss of auto-
inhibitory characteristics of Abl encoded by exon 1, which is lost in the translocation 
[90].  Abl kinase phosphorylates substrates on tyrosine and prefers a proline in the +3 
position, a motif that matches the CRKL-SH2 binding sequence [116].  CRKL was 
identified as a constitutively phosphorylated protein in neutrophils isolated from CML 
patients [91, 92].  The overactive BCR-Abl protein hyper-phosphorylates both CRKL and 
many CRKL-SH2 binding proteins, leading to over activation of CRKL signaling 
pathways including those controlling cell growth and proliferation [117].  The precise 
mechanism of transformation by CRKL in the presence of BCR-Abl is, however, 
unknown.  Importantly, propagation of signals from the BCR-Abl oncogene is unique to 
CRKL.  This is due to a regulatory mechanism found in CRK where phosphorylation of 
Y221 on CRK results in binding of its own SH2 domain, condensing the molecule, and 
blocking the binding of substrates to both the SH2 and SH3 domains [16].  The analogous 
site on CRKL, Y207, also appears to play an inhibitory role, and loss of this site results in 
greater association of CRKL with its SH2 substrates and increased ability to transform 
cells in culture [111].  The Y221 of CRK and Y207 of CRKL are the primary sites of 
phosphorylation by BRC-Abl [16, 25].  In spite of this, the phosphorylation on Y207 
does not appear to be sufficient to inhibitor the actions of CRKL in CML [110].  This 
constitutes one of the first differences observed between CRK and CRKL.  While they 
are analogous in some settings, they are not equivalent [68]. 
Another key role of CRK and CRKL was found downstream of integrin receptor 
proteins.  Integrins link the cytoskeleton of the cell to the extracellular matrix, and so are 
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critical for regulating growth and proliferation, cell motility, and adhesion [16, 67]. 
Associated with integrins on the cell surface are large protein complexes known as Focal 
Adhesions (FAs) which serve as the interface between the integrins and the cytoskeleton.  
Two major constituents of FAs are paxillin [10] and CAS [45, 98].  Interaction between 
integrins and the ECM induce clustering of integrins, which can directly activate Src 
kinase by interaction between integrin aIIbβ3-tails and the Src SH3 domain [3].  Upon 
CAS phosphorylation by Src, CRK/CKRL is recruited to CAS and binds phosphorylated 
YxxP sites.  Translocating with CRK and CRKL via binding to the SH3 domain are 
proteins such as DOCK 180, a GEF that activates primarily Rac1 [65], and C3G, which 
primarily activates Rap1 [124].  The close proximity of the GEF to the GTPase attached 
to the cell membrane results in exchange of GDP for GTP and activation of the GTPase.  
In the case of DOCK180, activation of Rac1 causes actin polymerization leading to 
extension of the membrane for cell crawling [16, 65].  Translocation of CRK and CRKL 
via their SH2 domain is critical to its function.  This is elegantly demonstrated in an 
experiment where fusing a farnesylation tag sequence from the Ki-ras protein to CRKL 
creates a construct which is forced to associate with the membrane [54].  This was shown 
to enhance the activity of the GTPase Rap-1 through the guanine nucleotide exchange 
factor (GEF) C3G, even in constructs where the SH2 domain was deleted [54].  GTPase 
activity did not increase, however, when the N-terminal SH3 domain was deleted, even in 
the farnesylated construct [54].  Similar results were observed by fusion of a paxillin 
targeting LIM domain to CRKL resulting in localization of CRKL to focal adhesions 
[74].  This fusion protein was able to rescue motility defects in cells deficient in Src, Yes, 
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and Fyn kinases (SYF cells) [74].  Together, these experiments demonstrated that both 
the SH2 and SH3 domains of CRK/CRKL are critical to its function.  The SH2 domain 
deletion can be rescued by targeting CRKL close to its SH2 substrates, but loss of the 
SH3 domain cannot be rescued as the molecule can no longer bind the activators that it 
normally brings into proximity with effectors. 
Yet another function of CRK and CRKL was discovered downstream of Dab-1 
in Reelin signaling, a critical component of development in the vertebrate brain. [5, 101].  
Reelin is a large extracellular protein that was found to be deleted in reeler mice, a 
mutation that arose spontaneously and resulted in uncoordinated animals with severe 
morphological defects in nervous tissues and especially the brain [21, 31, 101].  During 
neuronal development, progenitor cells differentiate and undergo radial migration 
towards the basal surface of the developing cortex. As they migrate, the cells encounter 
Reelin produced by Cajal-Retzius cells which binds to its receptors Very low–density 
lipoprotein receptor (Vldlr), and the Apolipoprotein E Receptor 2 (ApoER2) [20, 122].  
Binding of Reelin to these receptors results in the activation of Src kinase and 
phosphorylation of the adaptor Dab-1 at four sites including Y220 and Y232, inducing 
the binding of CRK and CKRL [5, 80].   Once CRK/CKRL is recruited, the same 
downstream molecules found in integrin signaling are able to influence migration, 
specifically the SH3 bound C3G activate Rap-1 to stabilize actin and stop migration [5].  
This causes the migrating neurons to detach from radial glia and join the corresponding 
layer of the developing cortex. 
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1.4. Evolution and Biology of Crk/CrkL: 
Considering the essential functions of CRK and CRKL, it is not surprising to find 
that the evolutionary origin of these proteins is ancient.  Comparison of genes encoding 
CRK/CRKL across species has found that these two exist as a single ancestral gene in 
invertebrates known as crka [114].  It is most likely that the genes diverged before the 
split between the last common ancestor of vertebrates and invertebrates, as all vertebrates 
have homologs of both crk and crkl [114].  Primitive crka genes can be found in many 
organisms, including animals as simple as Choanoflagellates and Choanozoa, and the 
origins of CRK/CRKL appear to be as old as the most basic elements of phosphotyrosine 
signaling [114]. 
The popular model organism C. elegans provided some of the first insight into the 
function of CRK and CRKL in animals.  The mutant worm lines ced-2, ced-5 and ced-10 
were observed to have similar defects where cell migration and engulfment of apoptotic 
cells were impaired [99].  The genes were found to encode proteins homologous to CRK, 
DOCK180, and Rac, respectively [99].  Thus, a mechanism highly similar to what is 
found in vertebrate integrin signaling also regulates motility of cells in the worm.  In the 
fruit fly, a drosophila homolog, dCRK, was found and shown to interact during muscle 
development with Drosophila Myoblast City (MBC), a close homolog of mammalian 
DOCK180 [36].  Subsequent investigation in the zebrafish found that CRK and CRKL 
interact with Dock1 and Dock5 during myoblast fusion in Danio rerio as well [89].  It is 
clear that from the humble worm to humans, CRK and CRKL are fundamental molecules 
required for processes such as development which require coordinated cell motility. 
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A great deal of insight into the roles of CRK and CRKL in vertebrates has been 
gained from knockout models in mice.  Loss of CRK or CRKL in mice results in 
phenotypes which, while similar in some respects, are distinct.  CRK-null mice mostly 
die late in embryonic development, with a few surviving until shortly after birth [94].  
Gross histological inspection showed several defects including cardiac defects, nasal 
deformation and cleft palate [94].  Similarly, most CRKL-null mice do not survive past 
E16.5, although a few survive past birth with minor craniofacial defects, or rarely with no 
observable phenotype [42].  Histology of recovered embryos revealed defects in many 
neural crest derived tissues including cranial ganglia, thymus, and craniofacial tissues 
[42, 86].  The expression of CRK and CRKL overlap in many tissues, and the inability of 
loss of one to compensate for loss of the other is consistent with biochemical findings 
that CRK and CRKL have at least some unique functions [79].  The variable and possibly 
incomplete phenotypic penetrance in CRKL-null mice that survived to later stages of 
development and the lethality of CRK loss made complete investigation of the resulting 
phenotypes difficult.  To address this, a double knockout mouse was generated using the 
Cre-lox system to restrict loss to the brain [95].  This allowed for investigation of mice 
throughout development and into adulthood in CRK, CRKL, and CRK/CRKL-null 
animals.  These mice were also useful because they could be compared to animals null 
for Reelin and Dab-1 [95].  The phenotypes of these animals all show severe defects in 
the development of laminar structures of the brain such as the cortex and cerebellum [5, 
95].  The cellular ectopia observed is also a hallmark of the reeler mutant mouse.  In 
normal development of the cortex, each successive wave of progenitor cells passes the 
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previous layer.  The youngest cells form the outermost layers and the oldest cells the 
innermost.  In reeler mice, these layers are essentially inverted, as progenitors do not 
receive the signal to pass the previous layer, and the younger cells accumulate beneath 
older layers.  These observations helped to establish that the roles of CRK and CRKL in 
the cell largely overlap, as a conditional loss of only CRK or CRKL in the brain 
displayed a mild phenotype compared to double-knockout animals which had severe 
defects [95]. 
In humans, CRK and CRKL are associated with some developmental disorders 
caused by chromosomal deletions.  Two relatively common examples are Miller-Dieker 
Lissencephaly Syndrome (MDLS) and deletion 22q11.2, more commonly known as 
DiGeorge Syndrome (DGS) [12, 85].  MDLS is characterized by congenital 
malformations caused by microdeletions in 17p13.3 [49].  While the primary effects 
appear to be caused by loss of genes encoding LIS1 and 14-3-3ε, a wide variety of 
deletions have been reported including loss of crk, which is associated with more severe 
MDLS [12].  A case study of a fetus bearing a 0.7Mb microdeletion on chromosome 17p 
which includes deletion of crk, and showed no abnormal morphology in ultrasound [14].  
The fetus was terminated at 19 weeks, and at that time was observed to have mild fascial 
dismorphism [14].  It seems therefore that loss of CRK leads to somewhat similar, if less 
severe, phenotype in humans compared to mice.  DGS presents more specifically as 
cardiac and craniofascial defects, typically caused by a 3Mb deletion on 22q11.  
Harbored within this deletion are tbx1, a transcription factor which is thought to drive 
most of the defects observed in the DGS phenotype, and crkl [57, 88].  Investigation in 
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mice has shown that CRKL null animals also display many of the defects observed in 
DGS [42, 88, 94].  Loss of both tbx1 and crkl in mice results in a much more penetrant 
phenotype than tbx1 alone, consistent with the incomplete penetrance observed in human 
DGS [41]. 
 
1.5. CRK/CKRL-SH2 Binding Proteins and SHD: 
While many signaling pathways that CRK and CRKL participate in have been 
elucidated, the array of defects observed in null animals suggests that others exist as well.  
It therefore seems likely that the list of proteins known to interact with Crk and CrkL is 
not exhaustive.  The Ballif lab has recently validated several novel Crk/CrkL interacting 
proteins by looking for proteins enriched in the Crk/CrkL SH2 binding motif YxxP 
followed by validation in cell culture experiments.  Several candidate have been shown to 
bind to CRKL-SH2 including ESDN1 and ESDN2 [109].  These previously 
uncharacterized interactions may represent important functions of CRK/CRKL in events 
that require signaling to the cytoskeleton such as axonal pathfinding and cell migration 
during development.  Indeed, it is likely that a large number of signals converge on 
CRK/CRKL, making identification of its interacting proteins essential. 
The Src Homology domain containing protein D (SHD) is a 320 amino acid protein 
which contains five YxxP sites.  It is a relatively uncharacterized protein suggested to be 
an adaptor because it contains an SH2 domain and is a relatively small protein.  SHD was 
first identified in 1997 by a yeast two-hybrid screen looking for proteins that act as 
substrates for Abl tyrosine kinase, using the kinase domain of Abl as the bait [93].  It has 
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been reported that SHD was expressed in the brain and nervous tissue as determined by 
northern blot in mice [93] and by RNA-seq in humans (human protein atlas) [123].  The 
function of this protein is unknown.  It has three closely related SH2 domain containing 
proteins, SHB, SHE, and SHF, of which only SHB is well represented in the literature.  
The subsequent chapters in this thesis will investigate the nature of the interaction 
between SHD and CRKL, and attempt to answer some basic questions about its 
biological role.  We first investigate the binding of SHD to CRKL via the CRKL-SH2 
domain, which requires the YxxP sites of SHD.  We show that the SHD/CRKL 
interaction can be induced by inhibiting tyrosine phosphatases using hydrogen peroxide, 
or by overexpression of Abl kinase.  We also show that Abl kinase phosphorylates SHD 
on Y144 and other sites, and that mutation of Y144 to phenylalanine reduces but does not 
abrogate binding to CRKL-SH2.  Subsequent investigation of the related proteins SHB, 
SHE, and SHF reveals that overexpression of Abl kinase also results in binding of SHB 
and SHE to CRKL-SH2.  Finally, we show that the zebrafish ortholog shdb is expressed 
in several areas of the nervous system during development, and knockdown of shdb 
results in several obvious defects including smaller eye size, which we have quantified.  
We therefore suggest that SHD represents an uncharacterized substrate of the CRKL-SH2 
domain critical for development of some areas of the nervous system.  Additionally, SHD 
and the closely related SHB and SHE might represent a group of CRK/CRKL binding 
proteins for which the outcome of this interaction is unknown.  Future research will aim 
to answer if the effects of shdb knockdown are dependent or independent of CRK/CRKL 
to direct further inquiry of SHD function biochemically and in the nervous system. 
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CHAPTER 2: THE SH2 DOMAIN-CONTAINING ADAPTOR PROTEIN SHD 
REVERSIBLY BINDS THE CRKL-SH2 DOMAIN 
 
 
2.1: Introduction 
 The CRK and CRKL proteins are important molecules in many biological 
processes and function in many phosphotyrosine-dependent signaling pathways.  CRK 
and CRKL play roles in diverse processes such as development, where these molecules 
are required for Reelin signaling in the development of the vertebrate brain, and cancers 
such as chronic myelogenous leukemia, where CRKL is a requirement for the oncogenic 
effects of the Philidelphia chromosome [5, 24, 91, 95, 105]. The actions of CRK and 
CRKL depend upon localization of the molecule to phosphorylated targets via their Src 
Homology 2 (SH2) domains. Upon binding, the enzymatic action of effectors which bind 
to their Src Homology 3 (SH3) domains can exert effects. While extensive research has 
identified many CRK/CRKL interacting proteins, the diversity of functions in which 
CRK and CRKL have been implicated in suggests that these lists are incomplete, and 
identification of additional interacting proteins could aid our understanding of 
CRK/CRKL dependent cell processes.  Interaction of the SH2 domain is particularly 
relevant, as this will determine where in the cell the protein may act, and identification of 
new SH2 interacting proteins might provide insight into a novel signaling pathway which 
utilizes CRK and CRKL, or mechanisms of CRK/CRKL regulation not currently known. 
We therefore attempted to find novel binding partners for the CRK/CRKL SH2 domain, 
starting with an in-silico screen for human proteins enriched in the CRK/CRKL-SH2 
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consensus binding motif, YxxP [108].  As a next step, proteins of interest would be 
expressed in cell culture and assessed for their ability to bind to the CRKL-SH2 domain.   
One protein of interest, the SH2 Domain-containing protein D (SHD) contains 
five YxxP sites which might bind the CRKL-SH2 domain. Herein we show that SHD 
becomes tyrosine phosphorylated by kinases endogenous to HEK 293 cells. SHD tyrosine 
phosphorylation was induced by treating cells with hydrogen peroxide (H2O2) to inhibit 
tyrosine phosphatase activity. When SHD was expressed in cells stimulated with H2O2 
SHD was induced to bind to the CRKL-SH2 domain in pulldown assays. We show that 
treating cells with inhibitors for Src Family Kinases (SFKs) or Abl/Arg tyrosine kinases 
prior to H2O2 stimulation reduces this interaction, and that co-expression of Abl kinase 
with SHD is sufficient to induce binding.  We go on to show that a mutant SHD with a 
Y/F mutation of the five YxxP sites is unable to be bind to CRKL when co-expressed 
with Abl.  Using mass spectrometry, we identified phosphorylation on Y144 within a 
YxxP motif by Abl. Mutation of this site alone to phenylalanine reduced, but did not 
abrogate Abl-induced binding of SHD to CRKL.  Finally, we show that the close 
relatives SHB, SHE, and possibly SHF, can also bind to CRKL-SH2 when co-expressed 
with Abl.  These findings show that SHD and its relatives are novel CRK/CRKL 
interacting proteins with the potentially to affect the regulation or dimensions of 
CRK/CRKL signaling mechanisms. 
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2.2. Materials and Methods 
Constructs and Plasmids: 
The V5-tagged SHD construct was obtained from DNASU (DNASU Plasmid 
Repository, The Biodesign Institute/Arizona State University) and consists of the cDNA 
sequence encoding human SHD (GenBank HQ448179) cloned into the mammalian 
expression vector pLX304 bearing a V5-tag fused in frame with the C-terminus of SHD.  
Flag-tagged SHB, SHD, SHE, and SHF were obtained from Origene (Rockville, MD 
20850) and consisted of the mouse cDNA sequence of SHB (NM_001033306), SHD 
(NM_001159523), SHE (NM_172530), or SHF (NM_001013829) cloned into the SgfI-
MluI restriction sites of the mammalian expression vector pCMV6 bearing a Myc-DDK 
(Flag) tag in frame with the C-termini of each protein.  The mouse SHD Y/F mutants 
were prepared at our request by BioBasic (Markham, Ontario, Canada) and were re-
inserted into the pCMV6-Entry vector. The human c-Abl construct, with a C-terminal 
Flag-tag, was a gift from A. Howe (University of Vermont), and was originally 
constructed in the Kufe laboratory (Harvard Medical School) [11].  The WT human Fyn 
construct in pRK5 was acquired from AddGene (Cambridge, MA, U.S.A.).  The bacterial 
expression vectors encoding the glutathione-S-transferase CrkL-SH2 fusion protein 
(GST-CrkL-SH2) was a gift from A. Imamoto (University of Chicago). 
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Cell culture and lysis, Transfections, and Cell treatments 
Human Embryonic Kidney 293 cells (HEK 293) were maintained at 37 °C under 
5% CO2 in a humidified incubator.  Cells were cultured in DMEM media (Mediatech, 
Manassas, VA) supplemented with 5% Fetal Bovine Serum (FBS) and 5% Cosmic Calf 
Serum (CCS) and antibiotics (sera were from Hyclone, Logan, UT).  HEK 293 cells were 
transfected with 2-10 μg of DNA, depending on the experiment, and when cells were at 
~70% confluence using calcium phosphate precipitation.  6-16 hours after transfection 
cells were washed with PBS and then returned to complete media for 12-24 hours. 
In experiments using small molecule inhibitors, media was aspirated off cells 
and complete media containing inhibitors was added for the specified times.  The SFK 
inhibitor Src-1 (EMD-Calbiochem, Billerica, MA) and the Abl kinase inhibitor Imatinib 
(STI571; Selleck Chemicals, Houston, TX) in DMSO were used at 2 μM and10 μM 
respectively, for 25 minutes prior to H2O2 stimulation, or 30 minutes prior to lysis in 
inhibitor experiments which did not use H2O2 stimulation.  Cells stimulated with H2O2 
were incubated for 15 minutes with 8.8 μM H2O2. 
To lyse cells, 10 cm plates of cells were placed on ice and media was aspirated off.  Cells 
were then gently washed with 1X PBS and then lysed with 1mL of lysis buffer (25 mM 
Tris pH 7.4, 137 mMNaCl, 10% glycerol, 1% Igepal) containing protease inhibitors (5 
μg/mL-1 pepstatin, 10 μg/mL-1 leupeptin, 1 mM PMSF), and phosphatase inhibitors (1 
mM NaVO3, 25 mM NaF, 10 mM Na2H2P2O7).  Plates were scraped using a cell scraper 
and lysates were transferred to a 1.5 mL Eppendorf tube and briefly vortexed.  Lysates 
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were then centrifuged at 12,000 rpm for 30 minutes at 4 °C and then transferred to a clean 
1.5 mL tube leaving the insoluble pellet behind.  Protein concentrations were determined 
using Bradford Reagent (VWR, AMRESCO Inc; Radnor, PA) and an Eppendorf 
BioPhotometer Plus (Eppendorf; Hamburg, Germany) with bovine serum albumin (BSA) 
standards.  Cell lysates were then standardized by diluting with the appropriate volume of 
lysis buffer. 
 
Immunoprecipitation and Calf Intestinal Phosphatase (CIP) Assay 
Depending on the experiment, standardized lysates containing 1-2 mg of total 
protein was immunoprecipitated (IP) using α-V5 mAb or α-Flag Affinity Gel (10 μl of a 
50% slurry in BCLB) at 4 °C overnight with rocking.  In experiments using the α-V5 
mAb for IP, 1.5 μg of antibody was added to 1.5 mg of total protein and incubated at 4 °C 
with rocking for 1 hour before adding 20 μL of a 50% bead slurry in cell lysis buffer 
made with 7.5 μL of protein A slurry (Rockland; Pottstown, PA, U.S.A.) and 7.5 μL 
protein G slurry (Biosciences, Allentown, PA, U.S.A.) washed once with PBS and eluted 
to 20 μL in lysis buffer. The extracts were then incubated at 4 °C overnight with rocking.  
The resin was washed 3X with cell lysis buffer before being prepared for SDS-PAGE or 
the phosphatase assay. 
The Calf intestinal phosphatase (CIP) treatment was administered to immune 
complexes after IP.  After the overnight incubation with cell lysates, protein A/G resin 
bound to αV5 antibodies were washed an additional time in PBS and diluted into 500 μL 
of CIP buffer (10 mM NaCl, 1 mM Tris-HCl pH 8, 10 mM MgCl2, 1 mM DTT) and 
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separated into two tubes. The buffer was aspirated off and the resin was resuspended in 
50 μL of CIP buffer. 2.5μL of CIP (1 U/μL) was added to one tube, and the CIP treated 
and untreated tubes were incubated in a dry block at 37 °C for 1 hour.  The samples were 
then denatured by the addition of 16.66 μL of 4X sample buffer and boiling at 95 °C for 5 
minutes before being subjected to SDS-PAGE. 
 
GST-CrkL-SH2 Pulldown assay 
Pulldown experiments used standardized lysates containing 1-2 mg of total 
protein.  The volume of beads added varied from 10-20 μL of 50% slurry depending on 
bead saturation with the GST-CRKL-SH2 construct.  GST-CRKL-SH2 beads were 
prepared by inoculating a 50 mL Lysogeny Broth (LB) with 50 μg/mL ampicillin with E. 
coli BL21 bearing the previously described construct.  The 50 mL culture was grown 
overnight at 37 °C with shaking and used to inoculate 500 mL of LB + ampicillin.  This 
culture was grown for two hours to reach log phase and then induced by the addition of 
β–D-1-thiogalactopyranoside (IPTG) to 1 mM.  The induced culture was incubated for an 
additional 3-4 hours, and then centrifuged (6,000 x g, 20 minutes).  The bacterial pellet 
was resuspended in 10 mL  bacterial lysis buffer (100 mM ethylenediaminetetraacetic 
acid (EDTA), 1 mM PMSF, and 10 μg/mL leupeptin and pepstatin-A in PBS), and lysed 
by sonication in six 30 second intervals with equal intervals on ice. After sonication, 1 
mL of 10% Triton-100 was added.  Lysates were mixed and then centrifuged in Oakridge 
tubes (12,000 x g, 20 minutes).  Pellets were discarded and the lysate was incubated with 
300 μL of a 50% slurry of glutathione (GST) coated sepharose beads (Biosciences, 
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Allentown, PA) at 4 °C with rocking overnight.  The GST-CRKL-SH2 beads were 
washed 3X with bacterial lysis buffer, 3X with sterile PBS and stored at 4°C in PBS.  
Aliquots of the culture before and after stimulation along with GST-CRKL-SH2 beads 
were subjected to SDS-PAGE and coomassie stained gel to confirm induction of bacteria, 
the quality, and approximate concentration of protein on the beads. 
 
SDS-PAGE, Antibodies, Western Blotting, Enhanced Chemiluminescence 
Protein samples were denatured with protein sample buffer (1X = 150 mM Tris 
(pH 6.8), 2% SDS, 5% β-mercaptoethanol, 7.8% glycerol, and 0.25 ng/ml bromophenol 
blue) at 95 °C for 5 minutes and separated by SDS-PAGE.  Whole cell extracts were 
diluted 3:1 with 4X sample buffer and 25 μL of 1X sample buffer was added to 
pulldowns and immunoprecipitations.   After denaturation, 20 μL of sample was loaded 
into the appropriate well using a Hamilton syringe and separated on a 10% acrylamide 
gel (30% (w/v) and 37.5:1 acrylamide:bis-acrylamide) with a 4.2% acrylamide stacking 
gel.  Gels were then run at 20 mA/gel for ~10 minutes until the protein reached the 
resolving gel, at which point the current was increased to 30 mA/gel. Gels were then 
either coomassie stained (0.1% coomassie brilliant blue R-250, 20% glacial acetic acid, 
40% methanol) for mass spectrometry, or transferred to a nitrocellulose membrane at 0.4 
A for 2-4 hours or at 0.2 A for 12-16 hours in transfer buffer (190 mM glycine, 25 mM 
Tris–base, and 20% methanol) using a submersible transfer unit.  After transfer, a 
reversible Ponceau stain (0.5% Ponceau and 1% acetic acid in H2O) was used to assess 
total protein levels.  Membranes were then washed with deionized water and blocked 
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with 5% dry milk in TBS-T (150 mM NaCl, 20 mM Tris–HCl, and 0.1% Tween 20) for 
20 minutes and then incubated at 4 °C with the primary antibody diluted in TBS-T with 
0.005% sodium azide for 16-24 hours.  Primary antibodies and dilutions used are the 
following: α-phosphotyrosine 4G10 (mouse mAb; 1:1000; EMD Millipore, Billerica,MA, 
USA), α-V5 (rabbit mAb 1:2000), α-Flag M2 (mouse mAb, 1:2000; Cell Signaling 
Technologies), α-Src (rabbit mAb; 1:2000; Cell Signaling Technology), α-Src pY416 
(rabbit mAb, 1:5000; Cell Signaling Technology), α-Abl (rabbit mAb; 1:1,000; Santa-
Cruz), and αAbl pY412 (rabbit mAb; 1:1000; Cell Signaling Technology).  Blots were 
washed with TBS-T and then incubated with Horseradish peroxidase (HRP) conjugated 
secondary antibody at RT for 2-4 hours.  Secondary antibodies and dilutions used were: 
α-mouse-HRP (goat IgG, 1:5000; EMD Millipore), α-rabbit-HRP (goat mAb; 1:5,000; 
EMD Millipore). 
Proteins were detected using enhanced chemiluminescence and X-ray film 
(ThermoFisher Scientific, Waltham, MA, USA), and film was developed using a Medical 
Film Processor SRX-101A (Konica Minolta Medical & Graphic, Tokyo, Japan). 
 
Mass Spectrometry 
We were unable to resolve the band containing human SHD from the heavy 
chain of the antibody, and so the band containing both was split into two pieces, of which 
the higher contained mostly SHD and less heavy chain.  Both sections were diced into 
approximately one millimeter cubes and then prepared for mass spectrometry as 
described previously, but without the steps for reduction and alkylation [13].  Briefly, 
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proteins were digested in-gel with sequence-grade modified trypsin in 50 mM ammonium 
bicarbonate for 8-12 hours at 37 °C.  The tryptic peptides were dried using a speed vac 
and then resuspended in 2.5% acetonitrile, 0.15% formic acid and separated by HPLC 
before MS/MS analysis on a linear ion trap-orbitrap (LTQ-Orbitrap) mass spectrometer 
controlled by Thermo XCALIBUR 2.1 software (Waltham, MA, USA) using the protocol 
described previously [109] and summarized below. 
Tryptic peptides were separated on a reverse phase HPLC column packed with 5 
μm C18 silica.  Peptides were loaded onto the column using solvent A (2.5% Acetonitrile, 
0.15% Formic acid) and eluted off the column using a gradient of solvent B (99.85% 
Acetonitrile, 0.15% Formic acid).  Eluting peptides and solvent were electrosprayed (2.1 
kV) into the instrument.  The precursor scan (360-1700 m/z) was followed by 10 low-
energy collision-induced dissociation (CID) tandem mass spectra.  The CID spectra were 
acquired for the two most abundant ions in the precursor scan, followed by targeted scans 
for SHD (see table 2.1 and 2.2). 
SEQUEST searches were performed using a forward and reverse 2011 Uniprot 
Human Protein database requiring tryptic peptides and permitting the following 
modifications: phosphorylation of serine, threonine, and tyrosine (+79.9663 Da), 
oxidation of methionine (+15.9949 Da), and acrylamidation of cysteine (+71.0371 Da). 
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2.3. Results 
 
SHD is reversibly tyrosine phosphorylated and shows H2O2-dependent binding to 
the CRKL-SH2 domain 
Having identified SHD in-silico as a protein enriched in the CRKL-SH2 binding 
motif, YxxP, we tested if SHD expressed in cells could become phosphorylated and bind 
to the CRKL-SH2 domain in pulldown assays.  Reactive oxygen species (ROS) such as 
H2O2 have been shown to inhibit tyrosine phosphatases with relatively high specificity 
[26].  Cells can be treated with H2O2 for short periods to block tyrosine phosphatase 
activity, allowing endogenous kinases to phosphorylate targets unopposed and increase 
the content of phosphotyrosine in the cell many fold [26]. 
Stimulation of HEK 293 cells transiently transfected with human SHD with 
H2O2 induced phosphorylation on SHD as visualized by western blotting 
immunoprecipitated SHD with an α-phosphotyrosine antibody (Fig. 2.1).  This signal is 
lost when extracts are treated with calf intestinal phosphatase (CIP) after the IP (Fig. 1a).  
A pulldown experiment using a glutathione S-transferase-CRKL-SH2 fusion protein 
(GST-CRKL-SH2) immobilized on glutathione agarose showed that phosphorylated SHD 
from H2O2-stimulated cells is able to bind the CRKL-SH2 domain (Fig. 2.1b).  
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Figure 2.1: Western blots of SHD immunoprecipitated from extracts of H2O2-stimulated HEK 293 
cells shows reversible phosphorylation on SHD and pulldown assays show the binding of SHD from 
the same extracts to the CRKL-SH2 domain. (A) Western blot of HEK 293 cell lysates transfected with 
a V5-tagged SHD construct and treated with water or H2O2 (WCE) or immunoprecipitated (IP).  Samples 
were probed on membranes with the indicated antibodies. (B) Western blots of HEK 293 cell extracts 
transfected with a V5-tagged SHD construct and treated with water or H2O2.  Lysates were subjected to 
immunoprecipitation (IP) with (WCE), immunoprecipitated (IP) or pulldown assay with a GST-CRKL-
SH2 construct and probed on membranes with the indicated antibodies.  Results from (A) were generated 
by Jaye Grundy Weinhert. 
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SHD is phosphorylated and induced to bind to the CRKL-SH2 domain when co-
expressed in cells with Abl. 
To understand the kinases responsible for the H2O2-dependent interaction of 
SHD with CRKL, we used small molecule kinase inhibitors prior to H2O2 stimulation.  
Pre-treatment with the inhibitor Src-1 for SFKs and the inhibitor STI571 for Abl/Arg 
kinases prior to H2O2 stimulation reduced the binding of SHD to CRKL-SH2 in cell 
extracts subjected to pulldown (Fig. 2.2).  While each inhibitor dramatically reduced 
the binding of SHD to the CRKL-SH2 domain, both inhibitors together did not 
abrogate binding completely, suggesting either incomplete inhibition of SFKs and 
Abl/Arg by Src-1 and STI571, or the involvement of additional kinases not targeted by 
these inhibitors. These results argue that both SFKs and Abl kinases are involved in the 
H2O2-induced interaction of SHD and CRKL.  To test if these kinases were sufficient 
for the interaction, the SFK Fyn and Abl was individually co-transfected with a Flag-
tagged mouse SHD construct. We used a Flag-tagged construct here as in the same 
experiment we used a Flag-tagged positive control (DCBLD2-Flag) which we have 
shown to be induced to bind to the CRKL-SH2 domain by both Fyn and Abl [108]. We 
observed that co-expression of Abl was sufficient to induce binding to the CRKL-SH2 
domain in pulldown assays, but co-expression of Fyn was not, even though both 
induced the binding of DCBLD2 to the CRKL-SH2 domain (Fig. 2.3). 
It was interesting that the Src-1 inhibitor was able to reduce H2O2-induced 
binding, but overexpression of the SFK Fyn did not induce SHD binding to the CRKL-
SH2 domain.  SFKs have been shown to be upstream of Abl activation following H2O2 
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stimulation, therefore we attempted to inhibit cells co-expressing SHD and Abl with 
both the Src-1 and STI571 inhibitors and found that Src-1 was able to reduce SHD 
binding to CRKL, and STI571 was able to block the interaction entirely (Fig. 2.4) 
[108].  These results suggest a role for Fyn and other SFKs upstream of Abl rather than 
directly phosphorylating SHD. They also suggest that Abl-dependent phosphorylation 
of SHD is rapidly reversibly given that a brief treatment with the inhibitors led to a 
dramatic decrease in the binding reaction. 
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Figure 2.2: Inhibition of SFKs or Abl/Arg reduces the H2O2-induced binding of SHD to the CrkL-
SH2 domain (n=2).  HEK 293 cells were transiently transfected with SHD.  Prior to lysis, cells were 
treated with the indicated inhibitor or DMSO for 20 minutes and then stimulated with 8.8 mM H2O2 for 15 
minutes.  Lysates were standardized and either immunoprecipitated with α-V5 (IP), subjected to pulldown 
with GST-CrkL-SH2 beads (PD) or run as whole cell extract (WCE).  Membranes were blotted by the 
indicated antibodies. 
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Figure 2.3: Abl kinase, but not Fyn, is sufficient to induce SHD to bind CrkL-SH2.  Human embryonic 
kidney (HEK 293) transiently transfected with the indicated constructs.  Lysates were subjected to 
pulldown with GST-CRKL-SH2 beads (PD) or run as whole cell extract (WCE).  Membranes were blotted 
with the indicated antibodies. 
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Figure 2.4: Inhibitors of SFKs and Abl/Arg reduce the Abl-induced binding of SHD to the CRKL-
SH2 domain (n=2).  HEK 293 cells were transiently transfected with the indicated constructs.  Prior to 
lysis, cells were treated with inhibitors or DMSO for 30 minutes. Lysates were subjected to pulldown with 
GST-CRKL-SH2 beads (PD) or run as whole cell extracts (WCE).  Membranes were blotted using the 
indicated antibodies. 
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The YxxP sites of SHD are required for the Abl-induced binding of SHD to the 
CRKL-SH2 domain. 
Given the CRKL-SH2 domain binds with high-selectivity to tyrosine 
phosphorylated YxxP motifs, it is likely that the interaction between SHD and the 
CRKL-SH2 is mediated by phosphorylation at one or more of the five YxxP motifs on 
SHD.  In order to test this hypothesis, we obtained a mutant Flag-tagged SHD with 
tyrosine mutated to phenylalanine at all five YxxP sites (SHD Y5F).  The mutant SHD 
Y5F was unable to bind CRKL-SH2 domain when co-expressed with Abl (Fig. 2.5). 
 
Abl induces the phosphorylation of SHD at Y144 
We next sought to determine if Abl induced the phosphorylation of specific 
tyrosines in YxxP motifs.  HEK 293 cells were transfected with V5-tagged SHD or co-
transfected with V5-tagged SHD and Abl.  Cell lysates were then immunoprecipitated 
with an α-V5 antibody, run on SDS-PAGE and then were analyzed by mass 
spectrometry to search for phosphorylation of specific YxxP sites.  We found two of 
the four tryptic peptides which harbor the five SHD YxxP motifs (Table 2.1) and 
identified phosphorylation at Y144 (Fig. 2.6a and 2.6b). The expected b- and y-type 
ions resulting from Collision Induced Dissociation (CID) of the precursor ions 
harboring Y144 and pY144 are shown (Table 2).  Several diagnostic ions allowed for 
verification of phosphorylation at Y144.  In the both the unphosphorylated and 
phosphorylate peptide spectra, the y-22
+2
 ion has an m/z close to the expected 1207.57.  
This ion contains all the amino acids C-terminal to Y144, and shows that no 
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modification is detected on these amino acids.  The y-23
+2
 ion has an increased m/z 
indicating the addition of tyrosine which is close to the expected value of 1289.07 in 
the unphosphorylated spectra, but in the phosphorylated spectra has an m/z of 1329.2.  
The extra mass is explained by the addition of phosphate to Y144.  This is supported by 
the detection of several peaks which match expected values of b-ions containing the 
phosphotyrosine. 
The spectra generated showed measurements of fragment ions that were 
predicted and no major peaks remained unresolved.  We were unable to detect other sites 
of phosphorylation in this experiment, and so were uncertain if phosphorylation at this 
site might be the requirement for interaction with the CRKL-SH2 domain.  To assess the 
functionality of this site, we obtained a Flag-tagged SHD Y1F construct bearing a Y-to-F 
mutation at Y144 (Fig. 2.7).  When co-expressed with Abl, the SHD Y1F protein was 
able to bind to the CRKL-SH2 domain, although the interaction was reduced compared to 
the binding of wildtype SHD. 
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Figure 2.5: The SHD Y5F construct bearing Y-to-F mutations at the five YxxP motifs is unable to 
bind to the CRKL-SH2 domain when co-expressed with Abl (n=1). HEK 293 cells were transiently 
transfected with the indicated constructs.  Lysates were subjected to pulldown with GST-CRKL-SH2 beads 
(PD) or run as whole cell extracts (WCE).  Membranes were blotted with the indicated antibodies. 
34 
 
 
 
 
 
Table 2.1: Summary of tryptic peptides of SHD which harbor YxxP sites detected in MS.  The table 
was generated using sequences and mass values from the Institute for Systems Biology protein digest tool.  
Detection of YxxP-containing peptides is indicated as detected or not, as is the tyrosine phosphorylated 
species.  PPM was calculated from MS1 experimentally measured m/z values and the expected m/z 
according to the protein digest tool for the M+3H
+
 ions of the indicated tryptic peptides. 
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Table 2.2: Predicted y-type and b-type singly and doubly-charged fragment ions from the M+3H
+
 
precursor ions harboring Y144.  The table was generated using values obtained from the Institute for 
Systems Biology fragment ion calculator tool (http://db.systemsbiology.net). 
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Table 2.3: Predicted y-type and b-type singly and doubly-charged fragment ions from the M+3H
+
 
precursor ions harboring phospho-Y144.  The table was generated using values obtained from the 
Institute for Systems Biology fragment ion calculator tool (http://db.systemsbiology.net). 
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Figure 2.6: The experimentally observed MS/MS spectra for the tryptic peptide harboring Y144 and 
pY144.  (A) The MS/MS spectra resulting from collision induced dissociation (CID) of the M+3H+ 
precursor ion containing Y144 (m/z = 992.13).  (B) The MS/MS spectra resulting from collision induced 
dissociation (CID) of the M+3H+ precursor ion containing phospho-Y144 (m/z = 1018.78).  Samples came 
from HEK 293 cells transfected with V5-tagged SHD or co-transfected with V-5 SHD and Abl kinase.  The 
phosphorylated precursor ion was only detected in condtions where Abl was also expressed. The b- and y-
type ions have been labeled.  No major peaks were unresolved. 
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Figure 2.7: The SHD Y144F mutant shows reduced binding to the CRKL-SH2 domain induced by 
Abl.  HEK 293 cells transiently transfected with the indicated constructs.  Lysates were subjected to 
pulldown with GST-CRKL-SH2 beads (PD) or run as whole cell extract (WCE).  Membranes were blotted 
by the indicated antibodies.  The doublet appearing in the Ponceau stain is due to breakdown of the GST-
CRKL-SH2 beads; however, the beads were still viable as demonstrated by their ability to bind to 
phosphorylated SHD in lanes 3 and 5 of the α-Flag blot of the GST-CRKL-SH2 pulldown (top blot). 
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SHD belongs to a family of SH2-domain containing proteins which are capable of 
interacting with the CRKL-SH2 domain. 
Having shown that H2O2 and Abl induce SHD to interact with the CRKL-SH2 
domain, and given that the related proteins SHB, SHE, and SHF also harbor YxxP motifs, 
we asked if Abl might also induce these family members to bind to the CRKL-SH2 
domain.  To investigate this, we transfected HEK 293 cells with Flag-tagged constructs 
of SHB, SHD, SHE, and SHF alone or co-transfected with Abl (Fig. 2.8).  We found that 
in addition to SHD, SHB and SHE also bind to CRKL when co-expressed with Abl.  A 
conclusion regarding the binding of SHF to the CrkL-SH2 domain was elusive given that 
SHF-Flag ran at the molecular weight of GST-CRKL-SH2 and the anti-Flag antibody had 
significant background binding to GST-CRKL-SH2. 
40 
 
 
 
 
Figure 2.8: The SHD family members SHB and SHE also bind to CRKL-SH2 when co-transfected 
with Abl (n=2).  HEK 293 cells were transiently transfected with the indicated constructs.  Lysates were 
standardized and subjected to pulldown with GST-CRKL-SH2 beads (PD) or run as whole cell extracts 
(WCE).  After SDS-PAGE gels were immunoblotted with the indicated antibodies.  Experiment replicated 
by Anna Schmoker (not shown). 
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2.4. Discussion and Future Directions 
Conclusions and Discussion: 
There is little published data available on SHD, so no comparisons can be made 
between these experiments and the literature.  While we have attempted to replicate as 
many experiments as possible, follow up will be necessary to better understand how 
CRKL is induced to bind SHD.  We have drawn several conclusions from the data 
presented. 
First, we have found that SHD can become phosphorylated in cell culture upon 
stimulation by H2O2 or by overexpression of Abl tyrosine kinase. It seems likely that Abl 
phosphorylates SHD directly, as the Abl-induced binding of SHD to the CRKL-SH2 
domain can be rapidly reversed by addition of the Abl inhibitor STI-571. While this 
provides some insight, it is unclear under what cellular conditions this phosphorylation 
normally occurs, or if any specific extracellular cues might lead to this interaction. The 
experiments we present using small molecule inhibitors suggest that even if Abl kinase is 
primarily responsible for phosphorylation of SHD in cells, multiple kinases including the 
SFKs, might play a role in regulating this event upstream of Abl. 
Observations from MS and pulldown experiments with SHD mutants indicate 
that SHD likely has multiple YxxP sites which can mediate binding to the CRKL-SH2 
domain. Although we only detected one site of phosphorylation in the MS experiment 
presented, subsequent mutation of this tyrosine to phenylalanine reduced but did not 
eliminate the Abl-induced binding of SHD to the CRKL-SH2 domain. The SHD Y5F 
mutant was unable to bind CRKL-SH2, and so at least one site other than Y144 and 
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potentially all five sites might facilitate the binding of SHD to the CRKL-SH2 domain 
upon phosphorylation.  
An important consideration is that SHD is a member of a family of SH2-
domain-containing proteins which include SHB, SHD, SHE, and SHF (Fig. 2.9).  We 
show that of these, murine Shb, Shd, and She bind CRKL-SH2 when co-expressed with 
Abl in cell culture (Fig. 2.8).  Shf may also bind, but it did not resolve from the GST-
CRKL-SH2 and so its binding was not observed.  It is also possible that murine Shf 
behaves differently than human SHF, as the Shf protein is 238 amino acids in length, 
compared to 438 in humans.  A large segment of the C-terminus is deleted, as well as 
another gap just C-terminal to the SH2 domain.  As a result, murine Shf contains only 
two YxxP sites, rather than the three found in humans.  However, these hypotheses 
remain to be tested fully. 
This SH2-domain-containing (SH) family of proteins is of interest to our lab 
group both because of their potential interaction with CRKL and their role in 
phosphotyrosine signaling via their SH2 domains. Given the importance of SH2 domains 
in cell signaling, proteins containing SH2 domains have been the focus of many large-
scale proteomics screens, some of which have included SHD and its family members [40, 
50, 58, 71]. The preferred SH2-domain binding sequences as determined by OPAL 
(Oriented Peptide Array Library) are Y(D/E)EL for SHB, Y(D/E)N(L/Y) for SHD, 
Y(N/D)xM for SHE, and Y(Y/F)E(L/Y) [50].  The preference for SHB had previously 
been reported to be Y(R/V/I)xL by a degenerate peptide library, although both methods 
agree that lysine (L) is required in the +3 position, and this position is generally regarded 
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as the primary determinant in SH2-domain substrate specificity [60, 87, 121].  In these 
motifs, the first Y is the phosphorylated tyrosine, followed by the +1, +2, and +3 
positions.  A “x” represents any amino acid (no preference).  Some amino acid 
preferences outside to residues 0 to +4 have also been identified, however the three 
amino acids following tyrosine account for most of the substrate specificity of SH2-
domains [69].  
This “SH” family of proteins represent an understudied group of adaptor 
proteins that may function to regulate CRK/CRKL.  The diversity of their structures 
could result in a number of subsequent interactions after binding to the CRKL-SH2 
domain.  SHB is better studied than the other family members, and has previously been 
reported to bind to CRK-II [77].  It was first identified as a serum-inducible gene product 
in an insulin producing pancreas cell line (βTC-1) [128].  SHB contains both a proline 
rich region near the N-terminus, a phosphotyrosine binding (PTB) domain, and an SH2 
domain near the C-terminus (Fig. 2.9).  The proline rich region is known to bind v-Src 
[60]. The SH2 domain can bind to fibroblast growth factor receptor-1 (FGFR-1) and 
vascular endothelial growth factor receptor-2 (VEGFR-2) [47, 60].  The PTB domain was 
shown to bind Focal adhesion kinse (FAK) downstream of FGF-2 to regulate cell 
spreading [46].  Abl kinase is known to phosphorylate SHB, which we have shown can 
induce binding between SHB and the CRKL-SH2 domain [44].  SHB has been implicated 
in wide array of functions, and its loss leads to notable vascular and immune defects in 
mice [43].  In cell culture, SHB alters differentiation in PC12 neuron-like cell lines, and 
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induces apoptosis in 3T3 fibroblast cells [61, 77].  It is widely expressed and seems to 
have numerous functions. 
Relatively little is known about SHD, SHE, and SHF.  From the structure of 
SHD, we have some proposed models for how SHD might interact with CRKL, and this 
might inform how the other family members behave to some extent as well (Fig. 2.11).  
One possible consequence of an SHD interaction with CRKL is the amplification of 
CRKL signaling, where SHD could aggregate CRKL molecules through its multiple 
YxxP sites.  This binding could also, however, be attenuating in nature, and by binding 
CRKL prevent it from localizing to CRKL-SH2 domain substrates.  A third and 
intriguing possibility is that CRKL would then be translocated to targets of the SHD-SH2 
domain, thus specifically altering CRKL signaling. These possible interactions are not 
necessarily mutually exclusive, and so our investigation into the YxxP sites will be 
necessary to resolve the potential complexity of these interactions.  We have designed 
some experiments to begin understanding the consequences of an SHD interaction with 
the CRKL-SH2 domain, which are outlined in the next section. 
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Figure 2.9: Protein schematic of human SHB, SHD, SHE, and SHF.  Schematics were generated using 
the IBS protein illustrator.  YxxP sites are indicated above the protein, an asterisk indicates tyrosine in 
YxxP motifs on which phosphorylation has been detected as reported at phosphosite.org.  Known domains 
are indicated: SH2 domains (blue) and PTB domain (green).  Predicted domains are also indicated: proline-
rich regions (red) and serine rich regions (yellow). 
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Figure 2.10: Alignment of human and murine SH family proteins.  Alignments were created using the 
Genius program with NCBI verified or predicted sequences.  YxxP sites are boxed and highlighted. 
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Figure 2.11: Hypothetical model for SHD molecular interaction with CRKL-SH2 domain.  The major 
domains within these proteins are indicated: SH2 domain (blue), SH3 domain (green), Proline rich regions 
(red), YxxP sites (yellow diamonds) and phosphorylation (yellow circles). The negative regulatory YxxP 
site on CRKL is also shown. The most likely outcomes of the SHD/CRKL interaction are signal 
amplification, attenuation, or alteration. 
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Future Directions: 
The function of SHD is currently unknown.  At its discovery, it was 
overexpressed in several cell lines and no obvious phenotypes were observed [93].  This 
could be explained by the requirement of binding to other proteins such as CRKL, which 
may only occur under specific conditions.  Future investigation into SHD should 
therefore take such considerations into account. 
A query of the proteomics database phosphosite (phosphosite.org) shows that 
phosphorylation has previously been detected on YxxP sites at Y144 and Y181 [48].  We 
would like to assess the ability of a mutant SHD with Y/F mutations at both of these sites 
to bind CRKL-SH2 when co-transfected with Abl kinase as a continuation of the 
experiments already described in this chapter.  Understanding the sites involved in the 
interaction between CRKL and SHD will inform future research into the role of SHD in 
cells.  Specifically, as we identify how these sites become phosphorylated either by Abl 
or other kinases, it will be possible to better understand where and when the interaction is 
induced in the cell, and what the outcome of the subsequent interaction with CRKL might 
be. We would also like to follow up with our observation that the Y1F SHD is still able to 
bind CRKL-SH2 by performing an α-Flag IP to purify Y1F SHD and WT SHD from 
cells co-expressing Abl kinase and blot for phosphotyrosine.  We would expect to see a 
reduction in phosphotyrosine signal corresponding to the reduced number of 
phosphorylated tyrosine residues.  This would support that the reduced binding is due to 
loss of phosphorylated YxxP motifs available to become phosphorylated.   We would 
also like to repeat the MS experiment and enrich our pool of phospho-SHD by using the 
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GST-CRKL-SH2 bead pulldown rather than the IP technique used in the experiment 
shown.  This may enable detection of additional phosphorylation sites and direct future 
experiments with mutant SHD constructs bearing Y/F mutations at sites identified in MS 
experiments to assess functionality of these sites in binding the CRKL-SH2 domain, with 
the goal being to understand the relative contribution of each YxxP site to the binding of 
SHD to the CRKL-SH2 domain. 
The binding of SHD to the CRKL-SH2 domain in these experiments suggest 
that SHD may play an important regulatory role.  The nature of this interaction is not 
currently known, however we have some hypotheses which will guide future 
investigation.  Based on the structure of SHD, we can think of three major mechanisms 
by which it could regulate CRKL cellular biochemistry.  This interaction could amplify, 
attenuate, or alter signaling of CRKL (Fig. 2.11).  The outcome of these interactions may 
be difficult to distinguish, but we have some experiments in mind to address this.  The 
first question that will need to be answered is if the interaction of SHD with CRKL will 
have any measureable effect in the cell.  To effectively investigate SHD in cell culture, 
there are some challenges which must be addressed. 
The first major challenge for investigation of SHD in cell culture will be to 
ensure that cellular conditions are amenable for SHD to become phosphorylated and bind 
the CRKL-SH2 domain.  Since we have identified Abl as a major inducer of SHD 
phosphorylation leading to an interaction with CRKL, this could serve as an initial 
mechanism of inducing the CRKL-SH2 interaction with SHD.    These cells, however, 
would likely not provide conditions under which SHD could bind CRKL.  While it would 
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be possible to transiently transfect Abl into cells to stimulate phosphorylation of SHD, 
the percentage of cells co-expression both the kinase and SHD would be likely be low, 
and would complicate analysis.  A stable transfection might provide a better model 
system, but overexpression of Abl typically needs to be high to overcome cell regulatory 
elements and result in a noticeable increase in phosphorylation of Abl substrates [97].  
Alternatively, this problem might be overcome by use of a mutant Abl, such as the BCR-
Abl found in Chronic Myelogenous Leukemia (CML) derived cell lines.  BCR-Abl has 
relatively high kinase activity in cells, primarily due to its lack of the N-terminal 
regulatory region where the translocation has caused fusion to BCR, and so the chimeric 
BCR-Abl would not be subject to many of the regulatory elements that normally inhibit 
c-Abl [90].  Importantly, BCR-Abl has been shown to phosphorylate SHD in cell culture 
previously [92].  A second challenge will be ensuring that CRK and/or CRKL are present 
and how to best measure their actions in the cell.  Some of the most crucial experiments 
for understanding the cellular function of CRK and CRKL have been cell motility assays.    
However CRK and CRKL have other measurable effects on cells, including cell 
proliferation.  In many cancers, CRK and CRKL contribute to rapid proliferation, as well 
as other factors that increase severity [35, 78, 126]. 
Taking these challenges into consideration, an effective experiment to 
understand the effect of SHD on CRK/CRKL signaling might be to start by asking how 
SHD affects CRK/CRKL-induced proliferation of a CML-like cell line. This can be 
demonstrated in Ba/F3 cells, which are interleukin-3 (IL-3) dependent.  The Ba/F3 cell 
line also expresses CRKL, and stable transfection of BCR-Abl into Ba/F3 by retroviral 
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infection transforms these cells to be IL-3 independent [23, 112, 113].  The proliferation 
of the Ba/F3 BCR-Abl cells could be quantified and compared to cells overexpressing 
SHD.  This could be accomplished by transfecting SHD, either transiently or stably.  A 
stable transfection might be preferable, as it would then be possible to ensure the entire 
cell population expressed SHD, simplifying analysis.  Since Ba/F3 cells are grown in 
suspension, the readout would be simple and proliferation could be measured by flow 
cytometry or using a hemocytometer after fixed numbers cells were allowed to grow for 
an allotted time.  If SHD reduces CRK/CRKL signaling, we would expect to see reduced 
proliferation in the Ba/F3 BCR-Abl cells overexpressing SHD.  If the cells show 
increased proliferation this would suggest signal amplification.  No change in 
proliferation might require a different experimental approach to investigate, but could 
occur especially if a significant amount of CRK/CRKL is active in the nucleus and is not 
available to be bound by SHD, as has been reported in some cases where BCR-Abl is 
overexpressed [100].  Another possible readout would be dependence on growth factors.  
Although we would have to first determine if the IL-3 independence observed in the 
Ba/F3 cells requires CRK/CRKL, this could serve as another readout for CRK/CRKL 
signaling, and could be determined using RNAi directed against CRK and CRKL.  If this 
prevented Ba/F3 BCR-Abl cells from becoming IL-3 independent, it would suggest we 
might be able to use SHD in a similar experiment.  If SHD attenuates CRK/CRKL 
signaling, the cells might lose the ability to grow without IL-3. 
If proliferation experiments prove problematic or inconclusive, another possible 
line of investigation could examine cell migration.  For example, the monkey kidney-
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derived cell line COS-7 have minimal migration behavior on collagen, but when 
transfected with CRK or CRKL this migration increases 4-fold or more [67].  These 
migration experiments can be performed and measured in a variety of ways.  Possibly the 
most widely used and comprehensive assay is the Boyden chamber [15].  This consists of 
two chambers separated by a filter containing pores through which cell must migrate.  
The most commonly used version measures haptotaxis, where cells migrate up a gradient 
of chemoattractant in a direction form of migration dependent on adhesion to a surface 
such as the ECM, rather than chemotaxis where a cell freely migrates up gradients in a 
fluid.  Haptotaxis describes the migration of cells which crawl along surfaces in processes 
such as wound healing, axonal outgrowth, and morphogenesis to name a few.  An 
experiment to examine COS-7 cells would measure therefore measure haptotaxis, as 
these cells require a surface on which to grow.  It is unlikely that SHD would become 
phosphorylated under normal COS-7 cell conditions, and so BCR-Abl could again be 
stably expressed in COS-7 cells to facilitate the interaction between SHD and the CRKL-
SH2 domain.  These COS-7 BCR-Abl cells would then have to be evaluated for baseline 
migration behavior.  Experiments could then be performed to test the effect of SHD on 
CRK/CRKL signaling.  In this system, we could compare COS-7 BCR-Abl cells to cells 
overexpressing SHD, overexpressing CRKL, or cells co-expressing SHD and CRKL.  As 
was previously reported, we would expect overexpression of CRKL, but not SHD, to 
increase migration of COS-7 cells.  It seems likely that co-expression of SHD with 
CRKL would either not result in little or no increase in migration above COS-7 BCR-Abl 
cells, and would be significantly less than cells expressing CRKL.  Assuming we see the 
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expected result, the Y5F SHD construct which cannot bind to CRKL-SH2 should not 
induce a significant change in proliferation compared to the cells expressing CRKL 
alone. 
The experiments outlined here might provide insight into the nature of the 
molecular interaction between SHD and the CRKL-SH2 domain which will be vital to 
understanding the role of SHD in the cell and ultimately in animals.  This will also begin 
to address the question of if SHD might have other roles outside of its interaction with 
CRKL.  If one or both of these experiments provide reproducible quality results, we 
could use them to investigate additional questions.  For example, if Ba/F3 BCR-Abl cells 
co-expressing SHD and CRKL are less proliferative than cell expressing only CRKL, 
would a SHD construct where the SHD-SH2 domain is deleted cause the same effect?  It 
would be interesting if loss of the SHD-SH2 domain changed its actions, as this would 
suggest that it has functional binding partners in our cell culture model.  We will have 
many questions to address as we better understand SHD and its interaction with CRKL.  
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CHAPTER 3: THE ROLE OF SHDB IN ZEBRAFISH EYE DEVELOPMENT 
 
3.1. Introduction 
While we have begun to characterize the protein-protein interaction between 
CRK-Like (CRKL) and Src Homology 2 Domain-containing protein D (SHD), the 
biological function of SHD is unknown.  To investigate SHD function in animals, we 
utilized the model organism Danio rerio, the Zebrafish. The zebrafish was chosen for 
several factors.  Importantly, crk and crkl are known to be expressed in the zebrafish 
and presumably have a similar function as in other vertebrates, as demonstrated by their 
interaction with the zebrafish Dedicator of cytokinesis 1 (Dock1, formerly Dock180) in 
myoblast fusion [89]. Use of the zebrafish was also advantageous for our investigation 
as the embryos develop quickly and externally, allowing for access to the embryo 
during development for manipulation.  Two orthologs of SHD exist in the zebrafish, 
Shda and Shdb.  An alignment shows that Shdb has greater homology to human SHD, 
and contains four of the five YxxP sites found in SHD, compared to three in Shda.  We 
therefore chose to initially characterize Shdb. 
We first wished to know where shdb was expressed in the zebrafish, and so 
performed in situ hybridization. Expression was observed in the developing nervous 
system, the head, and eyes.  This is roughly consistent with what is known about shd 
expression in mice and humans, where SHD is reported to be restricted to the nervous 
system [93].  The expression in and around the eye was of particular interest, as the eye 
develops in a stereotyped progression which is similar to other vertebrates including 
humans.  Recently CRK and CRKL have been implicated in aspects of eye 
55 
 
development downstream of FGF signaling [19].  Specifically, the FGF dependent 
elongation of fiber cells in the developing lens of the eye requires either Crk or Crkl, 
and conditional loss of both results in severe defects in elongation, while their 
differentiation was unaffected [19].  Since we observed expression of shdb in the lens, 
it is possible that Shdb functions in lens fiber elongation as well. 
We then sought to characterize how loss of shdb might affect the development 
of the fish.  Embryos were injected at the single cell stage with a morpholino (MO) to 
target shdb pre-mRNA.  These morphants displayed several defects, including cardiac 
edemas, hindbrain swelling, and small eyes.  RT-PCR shows that the dose of MO used 
in these experiments knocks down shdb significantly relative to a control gene ef1α.  
Given the severity of the defects observed, this suggests that Shdb is important for 
development of specific nervous tissues.  The role of this protein in these tissues is 
uncertain, and future research will aim to understand what this function might be. 
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3.2. Materials and Methods 
Zebrafish Husbandry 
All experiments were performed with approval of the University of Vermont 
Institutional Animal Care and use Committee (Protocol #17-031).  Zebrafish were 
maintained and bred under standard conditions as described previously [9]. 
 
Fish Lines and Transgenic Animals 
The zebrafish lines used in this work were the TL wild-type fish and the 
Spectrum of Fates (SoFa) fish, the latter of which was a generous gift from Bill Harris 
(Cambridge University).  The SoFa fish combine three transgenic lines harboring  
gapRFP driven under Atoh7, cytGFP under Ptf1a, and gapCFP under Crx [1].  This 
results in a transgenic animal where all 6 major neurons of the retina are differentially 
labeled in a window of time useful for developmental research. 
 
PCR, RNA Probes, and in situ Hybridization 
The shdb probe was generated from zebrafish cDNA using a forward primer 
harboring a SP6 site and reverse primer harboring a T7 site as described previously and 
underlined in the sequences below [103].  These primers were designed to bind to shdb 
~500 bp apart to allow generation of a RNA probe for in situ hybridization.  The primer 
sequences are as follows: 
FSP6: 5’ – TTTAGGTGACACTATAGAAGGGGGTGGTTCCATCAGCTCCAGT – 3’ 
RT7: 5’ – TAATACGACTCACTATAGGGGAGACTCTCTCCCCAATCATGGAA – 3’ 
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RNA probes were made from 100 ng of cDNA template combined with 1X 
transcription buffer (Promega), 10 μL of 20 mM dithiothreitol, 1X RNA labeling mix 
(Roche), 2 mg/mL RNA inhibitor (Invitrogen), and 2 U of DNAse (Ambion) and 
incubating at 37 °C for 15 minutes.  The RNA was then precipitated overnight at -20 °C 
after the addition of 104.5 μL of 10 mM EDTA and 100 mM LiCl in 100% EtOH.  RNA 
was spun down in an Eppendorf centrifuge (14,000 x g; 4 °C; 30 minutes), washed with 
70% EtOH and centrifuged for an additional 15 minutes at the same speed, before being 
air dried and resuspended in 20 μL of nuclease free water.  80 μL of hybridization buffer 
(50% formamide, 5X saline-sodium citrate (SSC), 5 mg/mL tRNA, 0.1% Tween-20) was 
added and the probe was stored at -20 °C. 
Embryos for in situ hybridization were collected and the chorion was removed 
manually.  Dechorionated embryos were fixed in 4% paraformaldehyde (PFA) in egg 
water at 4 °C for 24 hours.  The fixed embryos were then dehydrated in 100% methanol 
(MeOH) at 4 °C for 24 hours, and were stored in 100% MeOH at -20 °C until used.  To 
perform in situ hybridization, embryos were rehydrated with serial washes of PBT/MeOH 
increasing in the ratio of PBT to MeOH in increments of 25% until in 100% PBT.  The 
embryos were then permeabilized with 10 μg/mL proteinase K (Promega Corperation) for 
20 minutes for 36 and 48 hpf embryos, or 25 minutes for embryos older than 48 hpf.  
Embryos were then re-fixed in 4% PFA in PBT for 15 minutes and then washed 3 times 
with PBT for 5 minutes and then incubated at 70 °C for 12-24 hours with the shdb probe 
diluted 1:100 in hybridization buffer.  Following hybridization with the probe, the 
embryos were then equilibrated in 15 minute serial washes of hybridization buffer/2X 
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SSC at 70 °C, followed by two 30 minute washes at 0.2% SSC.  Embryos were 
rehydrated with 10 minute serial washes of 0.2% SSC/PBT into 100% PBT.  Embryos 
were incubated with α-digoxigenin-AP (Roche Diagnostics) diluted 1:5,000 in in situ 
block (Phosphate-buffered saline (PBS), 5% normal sheep serum (NSS), 1% BSA) at 4 
°C for 12-24 hours.  The embryos were then washed with PBT and stained with 1mM 
nitro-blue tetrazolium/5-bromo-4-chloro-3’-indolyphosphate (NBT/BCIP) (Thermo 
Scientific).  Staining was stopped by the addition of 4% PFA for 12-24 hours at 4 °C.  
Embryos were washed with PBT and stored at 4 °C until sectioned or imaged. 
 
Morpholino Design and Injection 
Splice inhibiting morpholino (MO) was purchased from Gene Tools (Philomath, 
OR, USA).  The shdb MO (sequence AGAAAAGCAGCAGAACTGACCTGTT) was 
designed to bind across the e3i3 boundary of SHD (Fig. 3.4).  Zebrafish embryos were 
injected at the single cell stage with 5 ng of MO as described previously [29].  Injected 
and uninjected control (UIC) embryos were incubated in egg water at 28.5 °C and staged 
according to (Kimmel et al.,1995) [64].  
 
Tissue Preparation and Resin Sectioning 
Embryos were reared to the desired time point and manually dechorionated, then 
fixed at 4 °C in 4% paraformaldehyde for 12-24 hours.  Embryos were then dehydrated in 
100% ethanol for a minimum of 2 hours followed by embedding using a JB-4 embedding 
kit (Polysciences, Inc.) as per the manufacturer’s instructions.  Embryos were manually 
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manipulated during embedding under a Nikon SMZ800 dissecting scope so that 
subsequent sectioning would result in transverse slices.  Embryos were sectioned on a 
Leica RM2265 microtome at a thickness of 7 μm.  Embryos stained by in situ were 
prepared using the same protocol and were cut to 20 μm thickness to allow visualization 
of the NBT/BCIP staining.  Sections were collected in order onto slides and stored at 
room temperature until imaging. 
 
Imaging and Measurements 
All bright field whole mount images were taken using a Nikon SMZ800 
dissecting scope with SPOT Insight camera operating on SPOT software (Diagnostic 
Instruments Inc.).  Higher magnification bright field images were taken on an Olympus 
IX71 fluorescent microscope using the same camera and software.  Image contrast and 
brightness was adjusted using Adobe Photoshop (Adobe systems Inc.).  Measurements 
were made using the SPOT software calibrated to the correct magnification. 
 
Graphs and Statistical Analysis 
 All measurements made in SPOT were exported to GraphPad Prism (V 6.0) for 
the generation of figures.  Comparisons were made using an unpaired Student’s t-test 
assuming equal variance.  Error bars represent the standard error of the mean.  The cutoff 
for statistical significance was P<0.05.  In the figures presented here, all P values are 
marked above the groups compared (all values ****: P<0.0001). 
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Alignments and Phylogenetic Tree: 
Sequences for phylogenetic trees and alignments were obtained from the NCBI protein 
database.  The Genius program  was used to generate alignments and subsequent 
phylogenetic trees [62]. 
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3.3. Results 
To understand the biological function of SHD, we first asked in what organisms 
it can be found.  We created a phylogenetic tree using NCBI predicted or verified protein 
sequences for Shd in 19 representative species.  Shd appears to be specific to vertebrates.  
A duplication event has produced two genes, shda and shdb, in bony fish (Fig. 3.1).  This 
is unsurprising as a large scale duplication in the lineage leading to zebrafish has resulted 
in the zebrafish bearing duplicate genes for ~20% of its genome [38].  Interestingly, the 
Shda found in zebrafish and in Japanese rice fish (Medaka) are more similar to each other 
than to Shdb of the same species, and could indicate a divergence of function between 
Shda and Shdb.  The avian sequences were automatically assigned to the out-group, and 
no unexplained clusters were observed in the tree. 
We then aligned human SHD with the homologs of several important vertebrate 
model organisms.  These were mouse and frog Shd, and zebrafish Shda and Shdb.  
Mouse Shb shares 81.1% homology with human SHD and shares all five YxxP sites.  
The Xenopus Shd and zebrafish Shda are less similar to human, and contain only three 
YxxP sites.  Shdb, is slightly more similar to human SHD with 62.3% sequence 
homology, and contains four of the five YxxP sites.  This includes the site analogous to 
human SHD Y144, which we have shown participates in CRKL-SH2 binding.  This site 
is not conserved in Shda, potentially making Shdb of greater interest for understanding 
SHD function as it relates to complexes involving CRK and CRKL. 
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Figure 3.1: Phylogenetic Tree of SHD in representative vertebrates.  The tree was generated using 
Genius software with NCBI-retrieved -verified or -predicted protein sequences. Sequences were assembled 
using the Jukes-Cantor genetic distance model with neighbor-joining and resampled using the bootstrap 
method with100 replicates. 
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Figure 3.2: Alignment SHD homologs from human, mouse, frog, and zebrafish.  The alignment was 
generated using Genius software (Blossum62 cost matrix; gap open penalty = 12, gap extension = 3) with 
NCBI-verified protein sequences.  YxxP motifs have been boxed and highlighted.  Conserved amino acids 
are highlighted with black, partially conserved (present in >50% of sequences) amino acids are highlighted 
in grey. 
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To identify where shdb mRNA is expressed in the fish, we designed primers to 
generate a ~500 bp RNA probe for in situ hybridization (Fig. 3.3 and 3.4).  Hybridization 
with the digoxygenin labeled probe and staining using an α-DIG secondary conjugated to 
HRP allowed for visualization by staining with NBT/BCIP.  The staining observed 
showed a variable expression pattern.  Imaging of 24, 36, 48, 60, and 72 hour post 
fertilization (hpf) embryos stained by in situ hybridization showed above background 
expression in several areas of the head, eye, and developing nervous system (Fig. 3.4).  
At 24 hpf, expression is observed in the Floorplate and the eye, primarily in the lens (Fig. 
2.4a). The expression in the eye decreases and is nearly absent by 48 hpf.  By 60 hpf, 
shdb is detected in several areas of the brain including the midbrain-hindbrain boundary, 
and is also seen in the fin buds.  We also see expression likely in the cerebellum in whole 
mount embryos starting at 48 hpf. 
Sectioning of embryos revealed more detailed expression in the eye and brain.  
At 24 hpf, shdb is strongly expressed in the developing lens and in the eminentia thalimi. 
This expression is also observed at 36 hpf, but is absent by 48 hpf.  Some expression is 
also detected in the developing tectum at early time points, just dorsal to the eminentia 
thalimi (Fig. 3.4 B’’). At 48 hpf, expression is detected in the cerebellum, and was 
detected at all subsequent time points (Fig. 3.4: C’’, D’, E’). 
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Figure 3.3: In situ hybridization of zebrafish embryo shdb mRNA expression during development.  
Lateral (A-E), dorsal (A’-E’), and 18 μM thick cortical sections (A’’-E’’) of zebrafish embryos stained with 
a digoxygenin-labeled antisense probe against shdb at the indicted time points. Credit goes in part to 
Ashley Waldron for her assistance making the shdb in situ probe. Areas of high expression have been 
annotated: Floorplate (Fp), Eminentia thalimi (EmT), Lens (Ls), Cerebellum (Ce), Finbuds (Fb), and 
Midbrain-hindbrain boundary (Mhb). 
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Zebrafish shdb morphant phenotypes 
We next sought to determine the effect that knockdown of shdb might have on 
the zebrafish during development.  Development is a critical period that requires precise 
coordination both within and between cells, and disruption of cell processes by 
knockdown can result in quantifiable phenotypes that provide clues about the functional 
mechanisms of the targeted gene transcript.  We observed demonstrable shdb expression 
in several areas of the nervous system, and so expected knockdown of shdb to present 
with defects in at least some of these areas. 
To knockdown shdb, we designed a morpholino (MO) to bind across the e3i3 
boundary of shdb pre-mRNA and disrupt splicing to form shdb mRNA lacking E3 (Fig. 
3.4).  The aberrant product introduces a stop codon in exon 5, producing a truncated 
201amino acid protein missense after exon 2.  Injection of the MO into zebrafish 
embryos at the single cell stage resulted in a dose-dependent phenotype.  The morphant 
phenotype included a reduction in eye size with a small or sometimes absent lens, 
swelling in the hindbrain, heart edemas, and defects in the body axis and a slight 
reduction in body size (Fig. 3.5).   
The reduced eye size was somewhat surprising given that expression was not 
observed to any great extent after about 48 hours post fertilization.  We quantified this 
small eye phenotype at a dose of 5 ng per embryo, as this produced fish that exhibited 
obvious phenotypes with a low mortality rate similar to un-injected control (UIC) 
animals.  To assess the effect of shdb knockdown specifically on the eye without bias due 
to smaller body size, we measured eye diameter and adjusted these values for the body 
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length of the fish.  The morphant fish had significantly smaller eyes at all time points 
examined, as determined by measure of eye size adjusted to body length (24 hpf, p = 3.17 
x 10
-5
; 48 hpf, p = 1.48 x 10
-7
; 72 hpf p = 3.37 x 10
-9
) (Fig. 3.5b).
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Figure 3.4: Schematic of the shdb MO design and RT-PCR verification of shdb knockdown.  (A) 
Schematic of the shdb MO design. The MO was designed to bind across the e3i3 boundary of shdb pre-
mRNA, resulting in deletion of exon 3 during splicing and a mature mRNA lacking e3.  The resulting 
protein is a truncated 201 amino acid protein missense after exon 2. (B) Agarose gel image of RT-PCR 
products. Template cDNA was made from RNA extracted from pooled un-injected control (UIC) or 
morpholino injected (MO) embryos at 72hpf. (C) Densitometry of bands normalized to the ef1α gene 
performed in Photoshop (Adobe). 
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Figure 3.5: Knockdown of shdb using morpholino results in reduced eye size relative to body length.  
Zebrafish embryos were injected with 5 ng of shdb MO at the single cell stage and allowed to develop for 
72 hours.  Images were taken of morphant and un-injected control animals at 24, 48, and 72 hour time 
points for comparison (A).  (B) The size of eyes, measured by diameter adjusted for body length, is less in 
MO injected than in control animals were significant at all time points as determined by unpaired student’s 
t-test assuming equal variance (**** = P < 0.0001). Credit goes to Alica Ebert for performing the MO 
injections. 
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3.4. Discussion and Future Directions 
Conclusions and Discussion 
Studying Danio rerio Shdb is likely to be informative for understanding SHD 
function due to its similarity to the human protein.  Our findings suggest that the four 
YxxP sites contained in Shdb will be sufficient to bind Crkl in the zebrafish.  The 
outcome of this interaction is unknown, and little is known about Crk or Crkl function in 
the zebrafish.  No currently published studies have explored how loss of Crk/Crkl affects 
the zebrafish.  As the interaction between SHD and CRKL is expected to be critical for 
the biological function of SHD, the lack of understanding of Crkl in the zebrafish may 
complicate resolution of these mechanisms.  Our collaborators in the Ebert lab are 
currently working to characterize crk and crkl mutant fish generated by Clustered 
Regularly Interspaced Short Palindromic Repeat (CRISPR), and once published this data 
will inform future studies into both CRK/CRKL and Shdb. 
The data presented here suggest that Shdb plays a role in the development of the 
eye and nervous system.  Despite the reduced eye size observed in Shdb morphants, the 
in situ hybridization did not detect any expression in the neural retina, although the 24 
hpf section reveals expression in and around the lens (Fig. 3.3).  There are many factors 
which could affect the size of the eye without directly acting on the neurons within.  
While an argument could be made that Shdb is perhaps involved in cell proliferation or 
death, the question remains as to why the eye is specifically affected.  Another 
consideration is if the mechanism of action for Shdb in the formation of the zebrafish eye 
is dependent or independent of Crk and Crkl, which is addressed in the next section.   
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The Small Eye Phenotype 
It is interesting that we see such a dramatic phenotype in the eye, considering 
the expression observed in the in situ hybridization where shdb is only found in the eye at 
early time points, and is largely absent by 48 hours post fertilization.   Despite this, the 
small eye phenotype persists and is still highly significant at 72 hpf.  We will continue to 
investigate how this might occur and there are several processes important for eye 
development that might be affected. 
The Ebert lab has found that defects in vascularization of the eye can result in 
reduced eye size [130].  However, the fact that 24 hpf shdb morphant fish already have 
significantly smaller eyes might preclude this possibility, as blood vessels do not begin to 
innervate the eye until about 48 hpf, and will not attach to the lens until 60 hpf  [2].  By 
this point, most shdb staining is absent in the eye.  Interestingly, a related family member, 
she, was reported to be significantly upregulated in a microarray screen using 
overexpression of Etsrp/Etv2 to induce genes involved in vascularization [129].  It 
remains an unlikely but also unresolved possible mechanism to explain the observed 
phenotype in shdb knockdown. 
A more likely mechanism could be through disruption of lens formation.  We 
observed that the lens in fish injected with MO appears to be reduced or even absent in 
many morphants (Fig. 3.4).  A recent investigation into fibroblast growth factor (FGF) 
signaling in the eye found that Crk and Crkl are required downstream of FGF for 
elongation of lens fibers in mice [19].  We have also observed expression of shdb in and 
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around the lens at 24 and 36 hpf.  The lens placode is mostly enveloped by the optic cup 
by 24 hpf, and begins to become visible under light microscopy around this time [22].  
By 36 hpf, the lens has separated from the surface ectoderm and is completely enveloped.  
At this point, the cells within the lens begin to differentiate into lens fiber cells [22]. A 
notable difference between zebrafish lens development and other vertebrates is that no 
hollow vesicle is formed in the lens during its development.  As development continues, 
the lens fibers elongate to expand the lens, and produce crytallin proteins.  The fiber cells 
undergo apoptosis as crystalline proteins build up, leaving a clear, crystallin filled lens 
capable of focusing light onto the retina [22].  If Shdb is indeed expressed in the lens as 
our in situ hybridization results suggest, it could be involved in Crk/Crkl signaling which 
is necessary for fiber cell elongation.  While it is possible that shdb is involved in another 
process such as differentiation of lens fibers, the lack of effect of loss of Crk/Crkl in mice 
on fiber cell differentiation make this unlikely [19].  This could be investigated by 
examining the developing lens using immunohistochemistry to look for crystalline, as if 
cells failed to differentiate they would fail to produce crytalline.  Fiber cell elongation 
could be quantified using H&E staining of sections from wildtype and morphant fish over 
a similar time course of 24-72 hpf. 
It is possible that other mechanisms might also be involved in the small eye 
phenotype of shdb morphants.  This phenotype is commonly seen in knockdowns which 
target components necessary for migration of optic vesicles, which detach from the 
forebrain and migrate bilaterally out to form the eyes [38, 81]. One example is PlexinA2, 
a semaphorin receptor classically involved in repulsive signaling during axonal guidance 
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which is also expressed in the eye fields early in development.  Knockdown of PlexinA2 
in zebrafish by morpholino results in a reduced eye size and was determined to occur 
primarily through loss of cohesion during migration of the eye fields early in 
development [27, 29]. Although we do not have data to support a role of Shdb in such 
early development, it is notable that the 24 hpf time point shows the greatest degree of 
expression in the eyes.  It is likely that if earlier time points were examined, we might 
find shdb expression in early optic vesicles. Since CRK and CRKL are known to play a 
role in neural development in neuronal migration in humans and mice, it also is plausible 
that Crk and Crkl might have a function in migration of the eye fields, although to our 
knowledge, this has not been investigated.  In mice, loss of Crk also appears to cause 
reduced eye size, although this was not quantified [42].  
 
Other shdb Morphant Phenotypes 
While the eye phenotype was initially quantified because it was so apparent, we 
have observed other defects in shdb morphants including hindbrain swelling and heart 
edemas.  The edemas are interesting as CRK and CRKL are known to have important 
function in cardiac tissue, and heart edemas are also observed in mice null for either CRK 
or CRKL [88, 94].  It is important to note that edemas are commonly seen in MO which 
exert off target effects, and so future experiments will need to address this to confirm if 
the edemas observed are indeed due to shdb knockdown.  The hindbrain swelling 
observed in morphant animals is interesting given that highly specific expression was 
observed in the in situ hybridization in the cerebellum and possibly other hindbrain 
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structurs.  Future experiments will aim to investigate this as an important potential 
function of Shdb in zebrafish. 
 
Future Directions 
 There are several follow up experiments that would help to both clarify the data 
presented and address unanswered questions.  We have shown that our shdb MO 
successfully knocks down shdb mRNA using RT-PCR (Fig. 3.4), however there are 
several control experiments that should be performed.  Knockdown using MOs is 
notorious for off target effects, and proper controls are important to verify that untargeted 
mRNAs are not being affected [6, 28].  Splice-inhibiting MOs such as the shdb MO used 
in these experiments tend to have fewer off target effects as they have more unique 
sequence compared to ATG-targeting (start codon) MOs [6]. Despite this, it will still be 
necessary to repeat these knockdown experiments with a second MO to validate the 
specificity of the knockdown.  A more immediate experiment to address the specificity of 
the MO will be rescue experiments.  We expect that injection of human or murine shd 
mRNA will rescue the eye size phenotype observed in shdb knockdown.  This will both 
help verify the effect of the shdb MO, and allow us to identify off target effects, as any 
effects not rescued by reintroduction of Shdb are likely to be off target effects.  
Importantly, if this rescue is successful, we can then attempt to rescue with the SHD Y5F 
construct.  We have shown that this construct is unable to bind the CRKL-SH2 domain.  
Therefore, if SHD Y5F is able to rescue shdb morphants, this would suggest that the 
function of Shdb in zebrafish eye development is independent of Crk/Crkl.  It seems 
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likely the Y5F construct will be unable to rescue shdb knockdown and that the interaction 
with Crk/Crkl is critical for Shdb function.  Determination of the shdb morphant small 
eye phenotype as dependent or independent of Crk/Crkl will be essential for designing 
future experiments. 
To continue investigation of how loss of Shdb affects the zebrafish, we will 
examine the histology of morphant animals.  H&E stained sections from control and MO 
injected animals will be compared to better understand the effects of shdb knockdown.  
This should provide information on specific regions of the eye and nervous system 
affected by knockdown, and will help resolve the question of why eyes are smaller in 
morphants since cell layers that are affected should be possible to identify in the highly 
stereotypical structure that is the eye.  We are interested to see if any of the areas we have 
observed expression are affected in morphant animals.  While we quantified the small eye 
phenotype, we would also like to see if the cerebellum appears normal in these fish.  The 
observed hindbrain swelling and shdb expression observed in in situs suggests that the 
cerebellum might have clearly observable defects in H&E stained sections.  Since the 
cerebellum is critical for motor functions, observation of swimming behavior could be 
assessed in shdb morphant or mutant zebrafish.  A simple experiment could record the 
startle response of these fish, as when disturbed they should swim away, and could look 
for abnormal swimming behavior or loss of coordination. 
Further characterization of the shdb small eye phenotype will still be important 
regardless of the rescue experiment results in regards to Shdb function dependence or 
independence on Crk/Crkl binding.  Two major factors in determining eye size are cell 
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proliferation and cell death [38, 75, 81].  A decrease in proliferation or increase in cell 
death will result in smaller eyes.  It will therefore be critical to evaluate these properties 
in the eyes of control and morphant animals to determine if these factors are involved, 
particularly at early stages when shdb expression is observed most in the eye.  
Proliferation can be assessed by immunostaining with antibodies for phospho-histone 3 
(H3) or for Ki-67.  Cell death can be detected by the popular Terminal deoxynucleotidyl 
transferase (TdT) dUTP Nick-End Labeling (TUNNEL) assay or an antibody against 
cleaved caspase-3, a terminal caspase important for both intrinsic and extrinsic cell death 
[39, 55]. 
 Finally, it will be important to examine time points earlier in development as the 
24 hpf in situ embryo data display strong expression in a number of areas in the eye and 
nervous system at this time, and morphant fish already have significantly smaller eyes.  It 
would be interesting to see how early shdb expression can be detected.  With regards to 
examining the effect on eyes before 24 hpf, an effective way to investigate such early 
periods of development is through the use of transgenic animals.  The Rx3 transgenic 
zebrafish labels precursor cells of the forebrain and early eye fields with GFP, and was 
used in the previously mentioned study into PlexinA2 loss in eye development [27].  This 
allows visualization and determination of the early eye fields when it is challenging to 
use light microscopy. 
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CHAPTER 4: RELATING MOLECULAR INTERACTIONS OF SHD TO 
BIOLOGICAL FUNCTION 
 
 
4.1. SHD Functions and Interactions 
 A critical component for understanding the biology of SHD will be to determine 
how its phosphorylation by Abl and subsequent interaction with the CRKL-SH2 domain 
relates to its function.  While we have not yet addressed this in our experiments, it is also 
possible that SHD has functions entirely independent of CRK and CRKL.  Our findings 
suggest that one mechanism for SHD signaling is likely through an Abl-SHD-
CRK/CRKL axis.  Here we discuss what we have discovered about SHD function and 
how it might be explained at least in part either by function of this Abl-SHD-CRK/CRKL 
axis or by SHD functions independent of Abl and CRK/CRKL. 
 
Lessons from Knockdown of Shdb 
 The zebrafish revealed two tissues which appear to be specifically affected by 
loss of shdb.  This is the eye, which was quantified, and the observed hindbrain swelling 
which has not been investigated in detail.  Since shdb expression was observed in the 
cerebellum, it seems likely that this is the major hindbrain structure affected.  The 
fundamental processes which underlie both eye development and cerebellar development 
might therefore provide insight into the function of Shdb.   This includes at least three 
processes including cell proliferation, apoptosis, and migration. 
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Cell proliferation is a critical component of nearly all developmental processes.  
At the stages of development we investigated, edemas such as we observed in the 
hindbrain can result from a hypoproliferation of normal tissue, causing fluid to 
accumulate.  Similarly, a proliferation defect would account for reduced eye size.  The 
opposite process, cell death, would also account for this underlying lack of tissue.   Both 
of these could be investigated using immunohistochemistry (IHC) to probe for markers of 
proliferation such as phospho-Histone H3 (pHH3) or Ki67, or assays for cell death such 
the cleaved caspse-3 antibody or the Terminal deoxynucleotidyl transferase (TdT) dUTP 
Nick-End Labeling (TUNNEL) staining assay.  Migration defects could also account for 
these phenotypes, as cells that failed to reach their targets would lead to loss of tissue in 
those areas.  Because the eye and cerebellum are both highly stereotypically-layered 
structures and so it might be possible to identify gross migratory defects in H&E stained 
sections. 
 
The Abl-SHD-CRK/CRKL Axis 
 While we have little data available to inform how SHD might function 
independent of CRK/CRKL, the experiments presented here suggest that SHD might 
have a role regulating CRK/CRKL signaling downstream of Abl kinase.   
 Abl and the Abl-related gene (Arg) make up the Abl family of non-receptor 
tyrosine kinases [70].  Like many other non-receptor tyrosine kinases, Abl and Arg 
contain modular protein domains to facilitate binding to other proteins, in addition to 
their enzymatic kinase domains.  Abl and Arg contain an SH2 domain, an SH3 domain, 
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and several proline rich regions to bind SH3 domains of other proteins including CRK 
and CRKL.  Abl is known to phosphorylate CRK at Y221 which negatively regulates 
subsequent CRK-SH2 binding [33].  The Abl family kinases were described to be unique 
from other non-receptor tyrosine kinases in that they contain both F-actin and G-actin 
binding domains near the C-terminus, which are not found in other tyrosine kinases 
[125].   
 In zebrafish, Abl is expressed throughout the developing animals and is 
particularly apparent in the nervous system [118].  Crk and Crkl are also observed 
throughout the developing nervous system [119].  The in situ hybridization we performed 
for shdb shows that expression is observed in the lens of the eye before 48 hpf, and is 
expressed in the cerebellum starting around 36-48 hpf.  It seems therefore that all the 
components of the Abl-SHD-CRK/CRKL axis are present in the tissues most affected by 
loss of shdb, suggesting that the interaction of SHD with the CRKL-SH2 domain might 
be necessary for many, if not all, of its functions.  We have also discussed the need for 
rescue experiments using the Y5F SHD construct, which lacks the YxxP sites critical for 
binding the CRKL-SH2 domain to address specificity of the morpholino and to allow for 
determination of phenotypes which require that SHD interacts with CRK/CRKL. 
 
4.2. Future Directions and Conclusions 
The developmental processes most likely affected by loss of shdb which might 
explain both the small eye phenotype and the hindbrain swelling are defects in cell 
proliferation, apoptosis, and migration.  Here we propose some experiments which will 
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provide valuable information for understanding if these processes are involved in defects 
resulting from the loss of Shdb.  This will direct future research and provide a framework 
for understanding the biology and molecular actions of SHD.  
 
SHD and Cell Proliferation 
 As discussed, we would like to examine shdb morphants for changes in cell 
proliferation using immunohistochemistry to evaluate markers such as pHH3 and Ki67.  
If loss of Shdb seems to have an effect on cell proliferation, the next logical step would 
be to attempt to determine what proliferative pathways might be involved, starting with 
the canonical Ras/MAPK pathway.  This is particularly relevant if Abl is involved, as this 
pathway is required for transformation of cells by the BCR-Abl oncogene [106].  Ras is 
activated by its Guanine Nucleotide Exchange Factor (GEF) Sos which is typically 
associated with the adaptor protein Grb-2 downstream of Receptor Tyrosine Kinases 
(RTK).  However, the CRK/CRKL-SH3 domain also binds to Sos.  It is possible that if a 
significant portion of the signal telling a progenitor to proliferate occurred through a non-
receptor tyrosine kinase, the signal could likely reach Ras through CRK or CRKL 
binding Sos rather than Grb-2.  Overexpression of CRKL is observed in many cancers 
and drives cell proliferation [78, 126].  If loss of shdb results in a reduction of 
proliferation, this would support a model in which SHD serves to amplify CRK/CRKL 
signaling.  This could occur by aggregation of CRK and CRKL by Shdb via the multiple 
YxxP sites on Shdb.  This would bring multiple copies of the effectors bound to the 
CRK/CRKL-SH3 domain into close proximity, increasing local activity of these effectors 
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potentially many fold.  Therefore, a loss of Shdb might result in a decrease in mitogenic 
Ras signaling, leading to reduced proliferation of precursor cells and hypodevelopment of 
tissue, explaining the reduced size of eyes and loss of tissue in the hindbrain. 
 
SHD and Cell Death 
 A lack of proliferation and an increase in cell death often appear very similar 
when examining gross histology of a morphant or mutant animal, and both can explain 
the absence of cells leading to smaller eye size and the tissue loss which most likely 
underlies the hindbrain swelling of shdb morphants.  In addition to proliferative markers, 
IHC can also be used to look for markers of apoptosis such as cleaved-caspase 3, or the 
TUNNEL assay.  We have discussed the possibility of Shdb regulation of Ras/MAPK 
activity through binding of CRKL bound to Sos.  While this is often a proliferative 
signal, under some conditions it can instead promote cell death.   In the classic signaling 
cascade, Ras activates Raf, which in turn activates ERK1/2.  At this point, ERK1/2 can 
translocate to the nucleus to interact with activator protein (AP-1) transcription factors 
such as Jun and Fos, or other mitogenic transcription factors such as Myc.  These 
transcription factors will promote cell survival and/or cell cycle progression.  However, 
signaling downstream of Ras is much more complicated.  For example, Ras also activates 
opposing pathways to control the fate of the cell.  Downstream of Ras, MAPK-activated 
Rsk and PI3K activated Akt promotes cell survival primarily by phosphorylating Bad 
[37, 115].  At the same time, Ras also activates RASSF1 and Nore1, which 
heterodimerize with Mst1, a serine/threonine kinase which increases caspase-3 activity 
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and promotes cell death [63].  Thus the outcome of Ras signaling depends on a complex 
stoichiometry of molecules that promote opposing outcomes.  It seems likely that if Shdb 
were to affect Ras signaling, an increase in cell death and a decrease in proliferation are 
both possible.  On the other hand, if Shdb were to attenuate CRKL-Ras-dependent cell 
proliferation, this would lead to decreased survival signaling and increased cell death.  
Assuming these hypotheses are correct, it would not be surprising to see either a lack of 
proliferation and increased cell death contributing to the loss of tissue underlying the 
reduced eye size and hindbrain swelling seen in shdb morphant fish. 
 
SHD and Migration 
 Migration is a fundamental process critical for the development of many tissues 
including the nervous system.  For eyes to form, early during development progenitor 
cells must bud off the telencephalon and migrate cohesively to reach the surface where 
they will contact the endothelium and invaginate, forming the optic cup which will 
continue developing into the adult eye.  Even after the eye fields have migrated to their 
final locations, the neurons of the retina will be born near the apical surface and must 
migrate to their final positions.  Similarly, the cerebellum contains three distinct layers: 
the granuale layer, the Perkinje cell, and molecular layer.  These arise due to coordinated 
migration of progenitor cells.  It is possible that Shdb might have a role in cell migration 
and this would help explain the effects we see in knockdown experiments.  Migration is 
one mechanism where it seems particularly likely that the action of Shdb occurs through 
CRK and CRKL signaling, as CRK and CRKL are critical components of cell migration 
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in numerous contexts.  It is well established that Reelin signaling is just as important for 
development of the cerebellum as it is in other areas of the brain such as the cortex [101].  
The function of CRK and CRKL in the eye has not been well investigated, recently it has 
been demonstrated that they are required for the elongation of lens fiber cells, and 
therefore development of the lens in the developing eye [19].  The fact that loss of shdb 
in the zebrafish does not affect more tissues that depend on CRK and CRKL functions 
might be explained by the expression pattern of shdb.  Alternatively, it is possible that 
shda compensates for loss of shdb in some tissues, although this remains to be 
investigated.  If CRK/CRKL signaling depend on Shdb either for signal amplification, or 
as a regulatory element if Shdb binding results in disruption of binding to Crk/Crkl-SH2 
domain substrates, migration behavior could be altered.  If the disruption is sufficient to 
prevent cells from reaching their destinations, they might fail to reach subsequent signals 
or growth factors that would allow them to continue to differentiate and/or proliferate.  
This would result in loss of tissue and explain the shdb morphant phenotype. 
 
Closing Remarks 
 Many questions remain about how SHD and Shdb functions.  Either through the 
Abl-SHD-CRK/CRKL axis we described or through another mechanism, further research 
will be necessary to understand how knockdown of Shdb has resulted in these defects.  
The research herein has laid the groundwork for future investigation.  As we learn more 
about SHD and Shdb, we will better understand both the function of the important 
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molecules CRK and CRKL, and the complex processes which govern the development of 
animals including humans. 
 
    
86 
 
BIBLIOGRAPHY 
 
1. Almeida, A.D., et al., Spectrum of Fates: a new approach to the study of the 
developing zebrafish retina. Development, 2014. 141(9): p. 1971-1980. 
2. Alvarez, Y., et al., Genetic determinants of hyaloid and retinal vasculature in 
zebrafish. BMC developmental biology, 2007. 7(1): p. 114. 
3. Arias-Salgado, E.G., et al., Src kinase activation by direct interaction with the 
integrin β cytoplasmic domain. Proceedings of the National Academy of Sciences, 
2003. 100(23): p. 13298-13302. 
4. Aten, T.M., et al., Tyrosine phosphorylation of the orphan receptor 
ESDN/DCBLD2 serves as a scaffold for the signaling adaptor CrkL. FEBS 
letters, 2013. 587(15): p. 2313-2318. 
5. Ballif, B.A., et al., Activation of a Dab1/CrkL/C3G/Rap1 pathway in Reelin-
stimulated neurons. Current biology, 2004. 14(7): p. 606-610. 
6. Bill, B.R., et al., A primer for morpholino use in zebrafish. Zebrafish, 2009. 6(1): 
p. 69-77. 
7. Birge, R.B., et al., Crk and CrkL adaptor proteins: networks for physiological and 
pathological signaling. Cell Communication and Signaling, 2009. 7(1): p. 13. 
8. Bjorge, J.D., A. Jakymiw, and D.J. Fujita, Selected glimpses into the activation 
and function of Src kinase. Oncogene, 2000. 19(49): p. 5620. 
9. Brand, M., M. Granato, and C. Nüsslein-Volhard, Keeping and raising zebrafish. 
Zebrafish, 2002. 261: p. 7-37. 
10. Brown, M.C., J.A. Perrotta, and C.E. Turner, Serine and threonine 
phosphorylation of the paxillin LIM domains regulates paxillin focal adhesion 
localization and cell adhesion to fibronectin. Molecular biology of the cell, 1998. 
9(7): p. 1803-1816. 
11. Cao, C., Y. Leng, and D. Kufe, Catalase activity is regulated by c-Abl and Arg in 
the oxidative stress response. Journal of Biological Chemistry, 2003. 278(32): p. 
29667-29675. 
12. Cardoso, C., et al., Refinement of a 400-kb critical region allows genotypic 
differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other 
phenotypes secondary to deletions of 17p13. 3. The American Journal of Human 
Genetics, 2003. 72(4): p. 918-930. 
13. Cheerathodi, M., J.J. Vincent, and B.A. Ballif, Quantitative comparison of CrkL-
SH3 binding proteins from embryonic murine brain and liver: Implications for 
developmental signaling and the quantification of protein species variants in 
bottom-up proteomics. Journal of proteomics, 2015. 125: p. 104-111. 
14. Chen, C.-P., et al., Prenatal diagnosis of a 0.7-Mb 17p13. 3 microdeletion 
encompassing YWHAE and CRK but not PAFAH1B1 in a fetus without 
ultrasound abnormalities. Taiwanese Journal of Obstetrics and Gynecology, 
2018. 57(1): p. 128-132. 
15. Chen, H.-C., Boyden chamber assay. Cell Migration: Developmental Methods 
and Protocols, 2005: p. 15-22. 
87 
 
16. Chodniewicz, D. and R.L. Klemke, Regulation of integrin-mediated cellular 
responses through assembly of a CAS/Crk scaffold. Biochimica et Biophysica 
Acta (BBA)-Molecular Cell Research, 2004. 1692(2): p. 63-76. 
17. Collett, M.S. and R. Erikson, Protein kinase activity associated with the avian 
sarcoma virus src gene product. Proceedings of the National Academy of 
Sciences, 1978. 75(4): p. 2021-2024. 
18. Collett, M.S., A. Purchio, and R. Erikson, Avian sarcoma virus-transforming 
protein, pp60src shows protein kinase activity specific for tyrosine. Nature, 1980. 
285(5761): p. 167. 
19. Collins, T.N., et al., Crk proteins transduce FGF signaling to promote lens fiber 
cell elongation. eLife, 2018. 7: p. e32586. 
20. D'Arcangelo, G., et al., Reelin is a ligand for lipoprotein receptors. Neuron, 1999. 
24(2): p. 471-479. 
21. D'arcangelo, G., et al., A protein related to extracellular matrix proteins deleted 
in the mouse mutant reeler. Nature, 1995. 374(6524): p. 719. 
22. Dahm, R., et al., Development and adult morphology of the eye lens in the 
zebrafish. Experimental eye research, 2007. 85(1): p. 74-89. 
23. Daley, G.Q. and D. Baltimore, Transformation of an interleukin 3-dependent 
hematopoietic cell line by the chronic myelogenous leukemia-specific 
P210bcr/abl protein. Proceedings of the National Academy of Sciences, 1988. 
85(23): p. 9312-9316. 
24. de Jong, R., et al., Crkl is complexed with tyrosine-phosphorylated Cbl in Ph-
positive leukemia. Journal of Biological Chemistry, 1995. 270(37): p. 21468-
21471. 
25. de Jong, R., et al., Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. 
Oncogene, 1997. 14(5): p. 507. 
26. Denu, J.M. and K.G. Tanner, Specific and reversible inactivation of protein 
tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid 
intermediate and implications for redox regulation. Biochemistry, 1998. 37(16): 
p. 5633-5642. 
27. Ebert, A.M., et al., Sema6a and Plxna2 mediate spatially regulated repulsion 
within the developing eye to promote eye vesicle cohesion. Development, 2014. 
141(12): p. 2473-82. 
28. Eisen, J.S. and J.C. Smith, Controlling morpholino experiments: don't stop 
making antisense. Development, 2008. 135(10): p. 1735-1743. 
29. Emerson, S.E., et al., Identification of target genes downstream of 
semaphorin6A/PlexinA2 signaling in zebrafish. Developmental Dynamics, 2017. 
30. Faderl, S., et al., Chronic myelogenous leukemia: biology and therapy. Annals of 
internal medicine, 1999. 131(3): p. 207-219. 
31. Falconer, D., Two new mutants,‘trembler’and ‘reeler’, with neurological actions 
in the house mouse (Mus musculus L.). Journal of genetics, 1951. 50(2): p. 192-
205. 
32. Feller, S.M., Crk family adaptors–signalling complex formation and biological 
roles. Oncogene, 2001. 20(44). 
88 
 
33. Feller, S.M., B. Knudsen, and H. Hanafusa, c-Abl kinase regulates the protein 
binding activity of c-Crk. The EMBO journal, 1994. 13(10): p. 2341. 
34. Feller, S.M., et al., SH2 and SH3 domains as molecular adhesives: the 
interactions of Crk and Abl. Trends in biochemical sciences, 1994. 19(11): p. 453-
458. 
35. Fu, L., et al., CRKL protein overexpression enhances cell proliferation and 
invasion in pancreatic cancer. Tumor Biology, 2015. 36(2): p. 1015-1022. 
36. Galletta, B.J., et al., Identification of a Drosophila homologue to vertebrate Crk 
by interaction with MBC. Gene, 1999. 228(1): p. 243-252. 
37. Gire, V., C. Marshall, and D. Wynford-Thomas, PI-3-kinase is an essential anti-
apoptotic effector in the proliferative response of primary human epithelial cells 
to mutant RAS. Oncogene, 2000. 19(19): p. 2269. 
38. Glass, A.S. and R. Dahm, The zebrafish as a model organism for eye 
development. Ophthalmic research, 2004. 36(1): p. 4-24. 
39. GORCZYCA, W., et al., DNA strand breaks occurring during apoptosis-their 
early insitu detection by the terminal deoxynucleotidyl transferase and nick 
translation assays and prevention by serine protease inhibitors. International 
journal of oncology, 1992. 1(6): p. 639-648. 
40. Grossmann, A., et al., Phospho-tyrosine dependent protein-protein interaction 
network. Mol Syst Biol, 2015. 11(3): p. 794. 
41. Guris, D.L., et al., Dose-dependent interaction of Tbx1 and Crkl and locally 
aberrant RA signaling in a model of del22q11 syndrome. Developmental cell, 
2006. 10(1): p. 81-92. 
42. Guris, D.L., et al., Mice lacking the homologue of the human 22q11. 2 gene CRKL 
phenocopy neurocristopathies of DiGeorge syndrome. Nature genetics, 2001. 
27(3): p. 293. 
43. Gustafsson, K., et al., Shb deficient mice display an augmented TH 2 response in 
peripheral CD4+ T cells. BMC immunology, 2011. 12(1): p. 1. 
44. Hägerkvist, R., et al., Consequences of Shb and c-Abl interactions for cell death 
in response to various stress stimuli. Experimental cell research, 2007. 313(2): p. 
284-291. 
45. Harte, M.T., et al., p130Cas, a substrate associated with v-Src and v-Crk, 
localizes to focal adhesions and binds to focal adhesion kinase. Journal of 
Biological Chemistry, 1996. 271(23): p. 13649-13655. 
46. Holmqvist, K., et al., The Shb adaptor protein causes Src-dependent cell 
spreading and activation of focal adhesion kinase in murine brain endothelial 
cells. Cellular signalling, 2003. 15(2): p. 171-179. 
47. Holmqvist, K., et al., The adaptor protein shb binds to tyrosine 1175 in vascular 
endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent 
cellular migration. Journal of Biological Chemistry, 2004. 279(21): p. 22267-
22275. 
48. Hornbeck, P.V., et al., PhosphoSitePlus, 2014: mutations, PTMs and 
recalibrations. Nucleic acids research, 2014. 43(D1): p. D512-D520. 
89 
 
49. Huang, H.-C., et al., Miller-Dieker syndrome with microdeletion of chromosome 
17p13. 3: report of one case. Zhonghua Minguo xiao er ke yi xue hui za zhi 
[Journal]. Zhonghua Minguo xiao er ke yi xue hui, 1997. 38(6): p. 472-476. 
50. Huang, H., et al., Defining the specificity space of the human SRC homology 2 
domain. Molecular & Cellular Proteomics, 2008. 7(4): p. 768-784. 
51. Hunter, T., The Croonian Lecture 1997. The phosphorylation of proteins on 
tyrosine: its role in cell growth and disease. Philosophical Transactions of the 
Royal Society of London B: Biological Sciences, 1998. 353(1368): p. 583-605. 
52. Hunter, T., Tyrosine phosphorylation: thirty years and counting. Current opinion 
in cell biology, 2009. 21(2): p. 140-146. 
53. Hunter, T. and B.M. Sefton, Transforming gene product of Rous sarcoma virus 
phosphorylates tyrosine. Proceedings of the National Academy of Sciences, 1980. 
77(3): p. 1311-1315. 
54. Ichiba, T., et al., Enhancement of guanine-nucleotide exchange activity of C3G 
for Rap1 by the expression of Crk, CrkL, and Grb2. Journal of Biological 
Chemistry, 1997. 272(35): p. 22215-22220. 
55. Jänicke, R.U., et al., Caspase-3 is required for DNA fragmentation and 
morphological changes associated with apoptosis. Journal of Biological 
Chemistry, 1998. 273(16): p. 9357-9360. 
56. Jensen, F.C., et al., INFECTION OF HUMAN AND SIMIAN TISSUE CULTURES 
WITH ROUS SARCOMA VIRUS. Proceedings of the National Academy of 
Sciences of the United States of America, 1964. 52(1): p. 53-59. 
57. Jerome, L.A. and V.E. Papaioannou, DiGeorge syndrome phenotype in mice 
mutant for the T-box gene, Tbx1. Nature genetics, 2001. 27(3): p. 286. 
58. Jones, R.B., et al., A quantitative protein interaction network for the ErbB 
receptors using protein microarrays. Nature, 2006. 439(7073): p. 168-174. 
59. Kantarjian, H.M., et al., Imatinib mesylate (STI571) therapy for Philadelphia 
chromosome–positive chronic myelogenous leukemia in blast phase. Blood, 2002. 
99(10): p. 3547-3553. 
60. Karlsson, T., et al., Molecular interactions of the Src homology 2 domain protein 
Shb with phosphotyrosine residues, tyrosine kinase receptors and Src homology 3 
domain proteins. Oncogene, 1995. 10(8): p. 1475-1483. 
61. Karlsson, T. and M. Welsh, Apoptosis of NIH3T3 cells overexpressing the Src 
homology 2 domain protein Shb. Oncogene, 1996. 13(5): p. 955-961. 
62. Kearse, M., et al., Geneious Basic: an integrated and extendable desktop software 
platform for the organization and analysis of sequence data. Bioinformatics, 
2012. 28(12): p. 1647-1649. 
63. Khokhlatchev, A., et al., Identification of a novel Ras-regulated proapoptotic 
pathway. Current Biology, 2002. 12(4): p. 253-265. 
64. Kimmel, C.B., et al., Stages of embryonic development of the zebrafish. 
Developmental dynamics, 1995. 203(3): p. 253-310. 
65. Kiyokawa, E., et al., Activation of Rac1 by a Crk SH3-binding protein, 
DOCK180. Genes & development, 1998. 12(21): p. 3331-3336. 
90 
 
66. Kleiman, L.B., et al., Rapid phospho-turnover by receptor tyrosine kinases 
impacts downstream signaling and drug binding. Molecular cell, 2011. 43(5): p. 
723-737. 
67. Klemke, R.L., et al., CAS/Crk coupling serves as a “molecular switch” for 
induction of cell migration. The Journal of cell biology, 1998. 140(4): p. 961-972. 
68. Kobashigawa, Y. and F. Inagaki, Structural biology: CrkL is not Crk-like. Nature 
chemical biology, 2012. 8(6): p. 504-505. 
69. Koch, C.A., et al., SH2 and SH3 domains: elements that control interactions of 
cytoplasmic signaling proteins. Science, 1991. 252(5006): p. 668-674. 
70. Koleske, A.J., et al., Essential roles for the Abl and Arg tyrosine kinases in 
neurulation. Neuron, 1998. 21(6): p. 1259-1272. 
71. Leung, K.K., et al., Enhanced prediction of Src homology 2 (SH2) domain 
binding potentials using a fluorescence polarization-derived c-Met, c-Kit, ErbB, 
and androgen receptor interactome. Mol Cell Proteomics, 2014. 13(7): p. 1705-
23. 
72. Levene, P. and C. Alsberg, The cleavage products of vitellin. Journal of 
Biological Chemistry, 1906. 2(1): p. 127-133. 
73. Levinson, A.D., et al., Evidence that the transforming gene of avian sarcoma 
virus encodes a protein kinase associated with a phosphoprotein. Cell, 1978. 
15(2): p. 561-572. 
74. Li, L., et al., Translocation of CrkL to focal adhesions mediates integrin-induced 
migration downstream of Src family kinases. Molecular and cellular biology, 
2003. 23(8): p. 2883-2892. 
75. Li, Z., et al., Modulation of cell proliferation in the embryonic retina of zebrafish 
(Danio rerio). Developmental Dynamics, 2000. 219(3): p. 391-401. 
76. Lipmann, F.A. and P. Levene, Serinephosphoric acid obtained on hydrolysis of 
vitellinic acid. Journal of Biological Chemistry, 1932. 98(1): p. 109-114. 
77. Lu, L., et al., NGF-Dependent neurite outgrowth in PC12 cells overexpressing the 
Src homology 2-domain protein shb requires activation of the Rap1 pathway. 
Experimental cell research, 2000. 259(2): p. 370-377. 
78. Lv, S., et al., CrkL efficiently mediates cell proliferation, migration, and invasion 
induced by TGF-β pathway in glioblastoma. Journal of Molecular Neuroscience, 
2013. 51(3): p. 1046-1051. 
79. Magdaleno, S., et al., BGEM: an in situ hybridization database of gene expression 
in the embryonic and adult mouse nervous system. PLoS Biol, 2006. 4(4): p. e86. 
80. Magdaleno, S., L. Keshvara, and T. Curran, Rescue of ataxia and preplate 
splitting by ectopic expression of Reelin in reeler mice. Neuron, 2002. 33(4): p. 
573-586. 
81. Malicki, J., et al., Mutations affecting development of the zebrafish retina. 
Development, 1996. 123(1): p. 263-273. 
82. Manning, G., et al., The protein kinase complement of the human genome. 
Science, 2002. 298(5600): p. 1912-1934. 
83. Mayer, B.J., M. Hamaguchi, and H. Hanafusa, A novel viral oncogene with 
structural similarity to phospholipase C. 1988. 
91 
 
84. Mayer, B.J. and H. Hanafusa, Mutagenic analysis of the v-crk oncogene: 
requirement for SH2 and SH3 domains and correlation between increased 
cellular phosphotyrosine and transformation. Journal of virology, 1990. 64(8): p. 
3581-3589. 
85. McDonald-McGinn, D.M. and K.E. Sullivan, Chromosome 22q11. 2 deletion 
syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine, 2011. 
90(1): p. 1-18. 
86. Miller, K.A., et al., A mouse splice-site mutant and individuals with atypical 
chromosome 22q11. 2 deletions demonstrate the crucial role for crkl in 
craniofacial and pharyngeal development. Molecular syndromology, 2014. 5(6): 
p. 276-286. 
87. Miller, M.L., et al., Linear motif atlas for phosphorylation-dependent signaling. 
Sci. Signal., 2008. 1(35): p. ra2-ra2. 
88. Moon, A.M., et al., Crkl deficiency disrupts Fgf8 signaling in a mouse model of 
22q11 deletion syndromes. Developmental cell, 2006. 10(1): p. 71-80. 
89. Moore, C.A., et al., A role for the Myoblast city homologues Dock1 and Dock5 
and the adaptor proteins Crk and Crk-like in zebrafish myoblast fusion. 
Development, 2007. 134(17): p. 3145-3153. 
90. Muller, A., et al., BCR first exon sequences specifically activate the BCR/ABL 
tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. 
Molecular and Cellular Biology, 1991. 11(4): p. 1785-1792. 
91. Nichols, G.L., et al., Identification of CRKL as the constitutively phosphorylated 
39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood, 
1994. 84(9): p. 2912-2918. 
92. Oda, T., et al., Crkl is the major tyrosine-phosphorylated protein in neutrophils 
from patients with chronic myelogenous leukemia. Journal of Biological 
Chemistry, 1994. 269(37): p. 22925-22928. 
93. Oda, T., et al., Identification and characterization of two novel SH2 domain-
containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase. 
Oncogene, 1997. 15(11): p. 1255-1262. 
94. Park, T.-J., K. Boyd, and T. Curran, Cardiovascular and craniofacial defects in 
Crk-null mice. Molecular and cellular biology, 2006. 26(16): p. 6272-6282. 
95. Park, T.-J. and T. Curran, Crk and Crk-like play essential overlapping roles 
downstream of disabled-1 in the Reelin pathway. The Journal of Neuroscience, 
2008. 28(50): p. 13551-13562. 
96. Park, T. and T. Curran, Essential roles of Crk and CrkL in fibroblast structure 
and motility. Oncogene, 2014. 33(43): p. 5121-5132. 
97. Pendergast, A.M., et al., Evidence for regulation of the human ABL tyrosine 
kinase by a cellular inhibitor. Proceedings of the National Academy of Sciences, 
1991. 88(13): p. 5927-5931. 
98. Polte, T.R. and S.K. Hanks, Interaction between focal adhesion kinase and Crk-
associated tyrosine kinase substrate p130Cas. Proceedings of the National 
Academy of Sciences, 1995. 92(23): p. 10678-10682. 
92 
 
99. Reddien, P.W. and H.R. Horvitz, CED-2/CrkII and CED-10/Rac control 
phagocytosis and cell migration in Caenorhabditis elegans. Nature cell biology, 
2000. 2(3): p. 131-136. 
100. Rhodes, J., et al., CrkL functions as a nuclear adaptor and transcriptional 
activator in Bcr-Abl-expressing cells. Exp Hematol, 2000. 28(3): p. 305-10. 
101. Rice, D.S. and T. Curran, Role of the reelin signaling pathway in central nervous 
system development. Annual review of neuroscience, 2001. 24(1): p. 1005-1039. 
102. Robinson, D.R., Y.-M. Wu, and S.-F. Lin, The protein tyrosine kinase family of 
the human genome. Oncogene, 2000. 19(49): p. 5548-5557. 
103. Rohs, P., et al., Neuronal expression of fibroblast growth factor receptors in 
zebrafish. Gene Expression Patterns, 2013. 13(8): p. 354-361. 
104. Rous, P., A transmissible avian neoplasm.(sarcoma of the common fowl.). Journal 
of Experimental Medicine, 1910. 12(5): p. 696-705. 
105. Salgia, R., et al., CRKL links p210BCR/ABL with paxillin in chronic myelogenous 
leukemia cells. Journal of Biological Chemistry, 1995. 270(49): p. 29145-29150. 
106. Sawyers, C.L., J. McLaughlin, and O.N. Witte, Genetic requirement for Ras in 
the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl 
oncogene. Journal of Experimental Medicine, 1995. 181(1): p. 307-313. 
107. Schlessinger, J., Cell signaling by receptor tyrosine kinases. Cell, 2000. 103(2): p. 
211-225. 
108. Schmoker, A.M., Driscoll, Heather E., Geiger, Stafanie R., Vincent, Jim J., Ebert, 
Alicia M., and Ballif, Bryan A., Bioinformatic screen identifies novel CRKL-SH2 
binding partners: an in silico motif-based approach to prioritize potential 
interacting partners. Bioinformatics, 2018. submitted. 
109. Schmoker, A.M., et al., Dynamic multi-site phosphorylation by Fyn and Abl 
drives the interaction between CRKL and the novel scaffolding receptors 
DCBLD1 and DCBLD2. Biochemical Journal, 2017. 474(23): p. 3963-3984. 
110. Senechal, K., J. Halpern, and C.L. Sawyers, The CRKL adaptor protein 
transforms fibroblasts and functions in transformation by the BCR-ABL 
oncogene. Journal of Biological Chemistry, 1996. 271(38): p. 23255-23261. 
111. Senechal, K., et al., Structural requirements for function of the Crkl adapter 
protein in fibroblasts and hematopoietic cells. Molecular and Cellular Biology, 
1998. 18(9): p. 5082-5090. 
112. Shah, N.P., et al., Multiple BCR-ABL kinase domain mutations confer polyclonal 
resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and 
blast crisis chronic myeloid leukemia. Cancer cell, 2002. 2(2): p. 117-125. 
113. Shah, N.P., et al., Overriding imatinib resistance with a novel ABL kinase 
inhibitor. Science, 2004. 305(5682): p. 399-401. 
114. Shigeno-Nakazawa, Y., et al., A pre-metazoan origin of the CRK gene family and 
co-opted signaling network. Scientific reports, 2016. 6: p. 34349. 
115. Shimamura, A., et al., Rsk1 mediates a MEK–MAP kinase cell survival signal. 
Current Biology, 2000. 10(3): p. 127-135. 
116. Songyang, Z., et al., Catalytic specificity of protein-tyrosine kinases is critical for 
selective signalling. Nature, 1995. 373(6514): p. 536. 
93 
 
117. ten Hoeve, J., et al., Cellular interactions of CRKL, an SH2–SH3 adaptor protein. 
Cancer Research, 1994. 54(10): p. 2563-2567. 
118. Thisse, B., et al., Expression of the zebrafish genome during embryogenesis. 
ZFIN direct data submission, 2001. 
119. Thisse, B. and C. Thisse, Fast release clones: a high throughput expression 
analysis. ZFIN direct data submission, 2004. 2. 
120. Thomas, S.M. and J.S. Brugge, Cellular functions regulated by Src family 
kinases. Annual review of cell and developmental biology, 1997. 13(1): p. 513-
609. 
121. Tinti, M., et al., The SH2 Domain Interaction Landscape. Cell Reports, 2013. 
3(4): p. 1293-1305. 
122. Trommsdorff, M., et al., Reeler/Disabled-like disruption of neuronal migration in 
knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell, 1999. 97(6): 
p. 689-701. 
123. Uhlen, M., et al., Towards a knowledge-based Human Protein Atlas. Nat 
Biotechnol, 2010. 28(12): p. 1248-50. 
124. van den Berghe, N., et al., Biochemical characterization of C3G: an exchange 
factor that discriminates between Rap1 and Rap2 and is not inhibited by Rap1A 
(S17N). Oncogene, 1997. 15(7): p. 845-850. 
125. Van Etten, R.A., et al., The COOH terminus of the c-Abl tyrosine kinase contains 
distinct F-and G-actin binding domains with bundling activity. The Journal of cell 
biology, 1994. 124(3): p. 325-340. 
126. Wang, J., et al., CRKL promotes cell proliferation in gastric cancer and is 
negatively regulated by miR-126. Chemico-biological interactions, 2013. 206(2): 
p. 230-238. 
127. Wapner, J., The Philadelphia chromosome: a genetic mystery, a lethal cancer, 
and the improbable invention of a lifesaving treatment. 2014: Workman 
Publishing. 
128. Welsh, M., et al., Shb is a ubiquitously expressed Src homology 2 protein. 
Oncogene, 1994. 9(1): p. 19-27. 
129. Wong, K.S., et al., Identification of vasculature‐specific genes by microarray 
analysis of etsrp/etv2 overexpressing zebrafish embryos. Developmental 
dynamics, 2009. 238(7): p. 1836-1850. 
130. Wysolmerski, E., FGF8a is Required for Proper Vascularization of the Zebrafish 
Retina. University of Vermont Theses and Dissertation, 2015. 
131. Zhou, S., et al., SH2 domains recognize specific phosphopeptide sequences. Cell, 
1993. 72(5): p. 767-778. 
 
 
